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Iron deficiency anemia is the most common nutrient deficiency in the world, 
with highest rates in pregnant women and young children. Despite the magnitude and 
severity of iron deficiency, there remains gaps in our knowledge of iron metabolism. 
Hepcidin is a key regulator of iron homeostasis yet limited data is available on its role 
during pregnancy. Although our knowledge of non-heme iron metabolism has 
increased substantially in recent years, the mechanisms regulating heme iron 
metabolism remain elusive.  The overall goal of this research is to further understand 
the primary determinants of iron absorption and placental iron transfer in women of 
childbearing age. 
 To address these issues stable iron isotopes (
57
Fe and 
58
Fe) were used to 
measure iron absorption in non-pregnant (ages 18-32 years, n = 30) and pregnant (ages 
16-32 years, n = 20) subjects and placental iron transfer in pregnant women. Non-
heme iron absorption was inversely associated with iron status and serum hepcidin. 
However, heme iron absorption was not significantly associated with serum hepcidin 
or iron stores, suggesting differential regulation. In a subset of 18 non-pregnant 
subjects serum prohepcidin (hepcidin precursor) was also assessed but was not 
significantly associated with measures of iron absorption or serum hepcidin. Both 
pregnant and non-pregnant women absorbed significantly more iron from a heme 
 based meal compared to a non-heme iron supplement. Interestingly there also appears 
to be preferential fetal utilization of maternally ingested heme iron compared to non-
heme iron during pregnancy.  Iron status in the maternal-neonatal dyad and maternal 
serum hepcidin were inversely associated with heme and non-heme placental iron 
transfer. In a cohort of 92 pregnant adolescents (ages 14-18 years), the placental 
protein expression of transferrin receptor was likewise increased in response to altered 
iron stores in the mother and neonate.  Despite increased iron absorption by women 
during pregnancy, placental iron transporter expression and placental iron transfer, 
many of the mothers and the neonates had suboptimal iron status at the time of 
delivery. Based on study results, further research on the mechanisms of heme iron 
metabolism and mechanisms of placental iron transfer are warranted.  
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CHAPTER 1 
 
INTRODUCTION
2 
 
Specific Aims 
Iron deficiency anemia is the most common nutrient deficiency in the world. 
The highest rates are in pregnant women and young children due to the increased iron 
requirements.  The prevention of iron deficiency during pregnancy is critical to avoid 
increased risk of labor and delivery complications, infant and maternal mortality, and 
potential long term adverse cognitive and developmental outcomes for the affected 
child (1). Iron homeostasis is meticulously regulated in response to iron stores, 
erythropoiesis and inflammation/infection through a complex system of post-
transcriptional regulation and hormonal (hepcidin) mechanisms. Although our 
knowledge of non-heme iron metabolism has increased substantially in recent years, 
the mechanisms regulating heme iron metabolism remain elusive. Furthermore, the 
dynamics of both heme and non-heme placental iron transfer during pregnancy are 
largely unknown. Accumulating data suggests that the ability to upregulate iron 
transfer to the fetus may not be sufficient to insure an optimal iron status in the 
neonate when maternal iron stores are limited. 
The goals of this research were fourfold: first, to characterize the relationship 
of serum hepcidin and prohepcidin to non-heme iron absorption in non-pregnant 
women; second, to characterize the determinants of heme and non-heme iron 
absorption in non-pregnant and pregnant women; third, to determine the role of 
maternal/infant iron status on heme and non-heme iron transport to the neonate; and 
fourth, to characterize determinants of  a key cellular protein involved in placental iron 
transport.  To address these issues stable iron isotopes were used to measure iron 
absorption in women of childbearing age and placental iron transfer in pregnant 
women. 
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The Specific Aims and Hypotheses are: 
I. To assess relationships between serum prohepcidin and hepcidin 
concentrations with iron absorption and compare the strength of these 
relationships between a non-heme food based matrix (orange-fleshed 
sweet potato) and a supplemental source of iron (ferrous sulfate).  
Hypothesis: Iron absorption is more significantly associated with serum 
hepcidin than prohepcidin and the strength of the relationships observed 
between regulatory compounds and iron absorption is stronger for 
supplemental non-heme iron sources than for food based non-heme sources. 
 
II. To assess the impact of iron status and serum hepcidin on heme and non-
heme iron absorption in non-pregnant and pregnant women. 
Hypothesis:  Iron absorption from both heme and non-heme iron is inversely 
related to iron status and serum hepcidin. However, the strength of these 
relationships will be higher for non-heme iron absorption than for heme iron 
absorption. 
 
III. To elucidate the determinants of heme and non-heme placental iron 
transfer to the neonate over the last trimester of pregnancy. 
Hypothesis:  Heme and non-heme placental iron transfer are inversely related 
to maternal and fetal iron status as well as maternal serum hepcidin.  
 
IV. To assess the relationships between placental TfR protein expression and 
maternal and neonatal iron status. 
 Hypothesis:  Expression of placental TfR protein expression is inversely 
related with both maternal and neonatal iron status. 
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The long-term goals of this project are: 
1. To provide data that will add to existing literature on the nutritional value 
of various sources of iron, based on their relative bioavailability. These 
data will provide additional information that may contribute to data used in 
the establishment of  US dietary guidance on iron intake recommendations. 
2. To elucidate mechanisms of maternal / fetal iron partitioning.  
3. To provide mechanistic information on proteins integral to placental iron 
transfer during pregnancy and determinants of their expression. 
 
Background and Significance 
Iron (Fe) deficiency anemia is the most common nutrient deficiency in the 
world, globally affecting over 1.6 billion people (2). The prevalence of iron deficiency 
is most severe in children and women in developing countries. However, it also 
prominent in industrialized nations as well and data for the U.S. indicates that 
approximately 7.8 million adolescent girls and women of childbearing age have iron 
deficiency and 3.3 million have iron deficiency anemia (3).  
The prevalence rates are even more alarming when the severe consequences of 
iron deficiency are considered.  These include: fatigue, impaired cognitive function, 
reduced work capacity, and decreased immunity (3;4).  Anemia during the first two 
trimesters of pregnancy has been associated with labor and delivery complications, 
increased risk of preterm delivery, low birth weight, reduced infant iron status, 
impaired mother-child interactions as well as infant and maternal mortality (5-8).  
Risks of iron deficiency during pregnancy are especially high because pregnancy 
associated iron losses approximate 480-1150 mg (including losses to the fetus, 
placenta and blood loss at delivery) (9). In a 55 kg woman the total iron requirement 
during pregnancy is approximately 1040 mg and corresponds to daily absorbed iron 
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needs of roughly 0.8 mg, 4-5 mg, and 6-8 mg/day for each of three trimesters of 
pregnancy, respectively (10). Many women struggle to meet the iron demands required 
for non-pregnant women (1.5 mg/day), so meeting these increased requirements 
during pregnancy from dietary sources alone is especially difficult. Pregnant 
adolescents are at an even higher risk of developing iron deficiency compared with 
pregnant adults because they also face the increased nutrient demands of growth and 
development. During adolescence, girls have a peak weight gain of 9 kg/year, which 
requires an additional 280 mg of iron to maintain circulating hemoglobin (Hb) 
concentrations (11). Thus, even otherwise healthy adolescents are at increased risk of 
developing iron deficiency due to these high iron demands. Over 60% of 1100 
pregnant African-American adolescents studied in a previous medical chart review in 
Baltimore, Maryland were anemic by the third trimester of pregnancy (12). 
Previous research has shown that pregnant women can upregulate non-heme iron 
absorption in response to iron deficiency, although absorption only increases by 1.5% 
for every 10 ug/L decrease in serum ferritin (measure of iron stores) concentrations 
(13). A number of studies have also shown increases in non-heme iron absorption 
across gestation even in iron replete women (14-17) and in non-pregnant women (18). 
However, to date no human studies to our knowledge have examined heme iron 
absorption during pregnancy. Despite the demonstrated upregulation of non-heme iron 
absorption, it may not be sufficient to insure adequate iron status in the neonate and 
mother. Unlike other minerals, once iron is absorbed, the body has no mechanism for 
excreting excess iron so the regulation and control of iron absorption at the enterocyte 
is vitally important. Iron absorption is meticulously regulated in response to iron body 
stores, erythropoiesis, and inflammation/infection through a complex system of 
posttranscriptional regulation and hormonal (hepcidin) mechanisms (19). 
Understanding of the hormonal control of iron absorption is a rapidly evolving; 
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hepcidin, the primary hormone believed to be responsible for the systemic 
coordination of iron homeostasis was only recently discovered in 2000 (20;21). Many 
questions remain regarding the mechanisms of heme and non-heme iron absorption 
and our knowledge of placental iron transport is extremely limited.  Further 
information is required on these mechanisms so that appropriate recommendations can 
be made to help insure adequate neonatal iron stores at birth. 
 
I.  Enterocyte Iron Metabolism 
Over the past decade, there have been immense advances in our knowledge of 
intestinal non-heme iron absorption and regulation (19). Dietary non-heme iron in the 
ferrous state (Fe
+2
) enters the enterocyte from the gut lumen through a divalent metal 
transporter (DMT1). Iron that reaches the gut in the ferric state can also be transported 
across the enterocyte but must first be reduced (Fe
+3 →
Fe
+2
) by duodenal cytochrome B 
(DCYTB) on the brush boarder (apical) membrane before it is transported by DMT1.  
Non-heme iron that enters the enterocyte is either stored as ferritin or exported across 
the basolateral membrane through ferroportin (FP-1), also previously referred to as 
iron regulated transporter protein-1. This export process involves hephaestin (Hp), a 
ferroxidase, which oxidizes ferrous iron to ferric (Fe
+3
) iron in order for it to be 
exported across the basolateral membrane via FP-1 and subsequently incorporated into 
serum transferrin (Tf).  
Intestinal uptake of heme Fe differs markedly from that of non-heme Fe. 
Recently the elusive heme transporter was thought to be discovered (heme carrier 
protein, HCP1) (22). However, upon further investigation,  Qui et al. demonstrated 
that HCP1 was actually a proton coupled folate transporter (PCFT) and a poor heme 
transporter at best, which leaves the primary heme transporter in both the intestine and 
placenta yet to be fully characterized (23). It has also been hypothesized that heme 
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iron is taken up by receptor mediated endocytosis, however, the mechanisms have not 
been worked out for this pathway either (24).  Furthermore, it is  currently unknown if 
once heme iron enters the intestinal cell if it is transported across the basolateral 
membrane intact via one of the recently identified heme transporters, BCRP (breast 
cancer resistance protein, also known as ABCG2) or FLVCR (feline leukaemic virus 
receptor C) (25;26). Alternatively, heme may be catabolized by heme oxygenase (HO) 
within the enterocyte so that it can then enter a common inorganic iron pool with non-
heme iron (27). Figure 1.1.a and Figure 1.1.b illustrate the pathways of iron 
absorption and the two proposed models of heme iron metabolism in the enterocyte. It 
is important to note that the true model may involve a combination of the two models. 
The ability to trace iron’s cellular flux through the unique use of stable iron isotopes in 
this research allows for further insight into heme iron metabolism. 
 
I a. Regulation of Enterocyte Iron Absorption 
Iron absorption is primarily influenced by the biochemical form of iron in the 
gut lumen (heme or non-heme), the iron status of the individual and the bioavailability 
of the iron source (based on meal composition and the presence of enhancers or 
inhibitors such as ascorbic acid and phytic acid, respectively) (28). Common non-
heme iron sources are staple crops such as rice, wheat, maize, and root crops. Non-
heme iron is the form of iron used in most iron supplements. Heme iron on the other 
hand, is found primarily from meat sources. Unfortunately, meat is often beyond the 
reach of the poor due to price and availability or religious/cultural beliefs. In many 
countries non-heme iron provides the primary source of dietary iron. Heme iron is 
readily absorbed, is less influenced by iron status and is less affected by other dietary 
factors compared with non-heme iron (28;29). The percentage of heme iron absorbed 
is roughly 5-10 fold higher than that of non-heme iron (29).   
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Figure 1.1.a Mechanisms of Iron Absorption I 
Heme iron is catabolized by heme oxygenase (HO) and enters an inorganic iron pool 
with non-heme iron and thereafter joins the same intracellular pathway as non-heme 
iron. 
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Figure 1.1.b Mechanisms of Iron Absorption II 
Heme iron does not enter the inorganic iron pool in the enterocyte and is exported  
across the basolateral membrane intact.  
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Iron status of the individual and iron bioavailability have been reported to alter 
non-heme iron absorption up to 10 to 15 fold (29).  The body has evolved a complex 
system of regulation of the expression of the proteins involved in cellular iron 
transport. In response to body iron stores and inflammation, specific iron regulatory 
proteins (IRPs) are up or down regulated to alter cellular iron transport (30).  There are 
two known IRPs (IRP-1 and IRP-2) which are distinct in their regulation, tissue 
expression and modulation despite being structurally and functionally alike (31). 
These IRPs bind to specific iron response elements (IREs) located in the 3’ or 5’ 
untranslated regions (UTR) of mRNAs that encode for key iron transport proteins and 
allow for post-transcriptional, iron-dependent regulation.  Depending on whether the 
IRE is located in the 3’ (as found for transferrin receptor, TfR) or 5’ (as found for 
ferritin) end of the UTR, binding of iron regulatory proteins (IRP) may stabilize or 
inhibit the translation of key iron proteins in response to cellular iron status. In 
conditions when the cell is iron-loaded, IRP-1 assembles an iron-sulfur cluster (4Fe-
4S) preventing IRE binding and IRP-2 undergoes proteasomal degradation (31). This 
up or down regulation of target genes using the same IRP allows for coordinated shifts 
from production of either iron storage proteins or iron transport or export proteins in 
response to body needs.  Using murine pro-B lymphocyte cell lines, researchers have 
demonstrated that IRP-2 was capable of functioning as the only IRE-dependent 
mediator of iron homeostasis and that regulation of ferritin and TfR expression was 
not dependent on IRP-1 (32).  In addition, IRP-1 knockout mice did not lead to any 
apparent abnormal phenotypes (33), while IRP-2 knockout mice exhibit aberrant iron 
homeostasis and iron accumulation in the intestine and certain areas of the brain (34).  
However, further research on the relative roles of IRP-1 and IRP-2 is needed. 
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Hepcidin is a small cysteine rich peptide hormone that has recently emerged as 
a key regulator of iron homeostasis (35). Hepcidin, initially referred to as LEAP-1, 
was discovered as an urinary antimicrobial peptide synthesized in the liver (20;36) that 
could be induced by both high iron status and inflammation (21).  Further research has 
also demonstrated that hepcidin expression may also be diminished in response to 
increased erythroid drive, hypoxia, and iron deficiency (37).  Hepcidin is believed to 
impact iron metabolism through four primary pathways: regulation of iron absorption 
in the gut; iron recycling from macrophages; control of hepatic iron storage; and 
regulation of placental iron transport to the fetus during pregnancy (35). Hepcidin 
regulates iron absorption by binding to ferroportin (the basolateral iron export protein) 
leading to its internalization and degradation within lysosomes (38). The loss of 
ferroportin effectively blocks iron export from the enterocyte, leading to a reduction in 
intestinal absorption. Recent research also suggests hepcidin may inhibit apical iron 
uptake in intestinal cells, and its role in regulating iron metabolism is cell dependent 
(39). Due to technological issues of measuring serum hepcidin, only within the past 
year has a relationship between serum hepcidin expression and iron absorption in 
humans been demonstrated in women, Chapter 2, (40) and men (41). Although a 
number of factors have been identified that may influence non-heme iron absorption, 
to date no studies have examined both heme and non-heme iron absorption during 
pregnancy. This study will provide novel data on the key determinates of both heme 
and non-heme iron absorption.  
 
II. Placental Iron Transfer During Pregnancy 
The placenta is a unique temporary organ that functions as the fetus’s lungs, 
kidneys, digestive system, liver, endocrine and immune system in order to ensure the 
growth and development of the fetus. The placenta is able to mediate the transmission 
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of nutrients to the fetus.  Humans have a hemochorial placenta; indicating that the 
maternal blood is in direct contact with the fetal chorionic villi (42).  In the mature 
hemochorial placenta there are only two layers separating maternal and fetal blood, the 
syncytiotrophoblast (STB), and fetal endothelial cells. The STB is able to selectively 
regulate transport of oxygen and essential nutrients to the fetus while also allowing for 
the excretion of fetal waste products (ex. carbon dioxide) to be cleared by maternal 
circulation.  
During the third trimester of pregnancy the majority of fetal iron stores are 
acquired and many nutrients such as iron are actively transported across the STB 
against a concentration gradient. This placental iron transfer may set the stage for 
postnatal iron status and the risk of developing iron deficiency in infancy.  The 
neonatal gut is immature and is not able to regulate iron metabolism so iron stores at 
birth are very important. Therefore, understanding mechanisms of fetal iron transport 
during the third trimester of pregnancy is important to ensuring adequate iron 
endowment at birth.  
Within the placenta iron is absorbed across the microvillar membrane (also 
known as apical or maternal membrane), transferred across the cytoplasm of the STB, 
exported through the basal fetal membrane and then transported across the fetal 
endothelial lining before reaching the fetal circulation. Placental iron transport is 
depicted in Figure 1.2; however it is important to note that this diagram is a best 
estimate of iron transport and is not nearly as scientifically robust as the enterocyte 
model.   
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Figure 1.2 Mechanisms of Placental Iron Transport 
Maternal iron is transported across the apical membrane of the syncytiotrophoblast 
(STB) by receptor mediated endocytosis, transferred across the cytoplasm of the STB, 
through the basal fetal membrane, across the fetal endothelial lining and then is 
released into the fetal circulation. The mechanisms by which this transport occurs 
remain elusive and require further investigation. 
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Transferrin receptor (TfR) is expressed on the apical (maternal) side of the 
STB membrane where it is responsible for binding maternal transferrin (43).  Once 
bound, this transferrin-TfR complex is internalized into clathrin-coated endosomes by 
receptor mediated endocytosis. This process is believed to occur as previously 
reported for other tissues, where the pH of the endosome is decreased with a proton 
pump to release the iron from transferrin and the apo-Tf and TfR are recycled to the 
cell membrane to repeat the cycle (44). Iron is likely released from acidified 
endosomes into the cytoplasm via divalent metal transporter 1 (DMT1) (45).   
 Recent research has questioned the essentiality of DMT1 in the placenta, as 
murine data found that although DMT1 was vital for intestinal non-heme iron 
absorption after birth, DMT1 was not required for placental iron transfer (46). An 
alternative or complementary route for iron uptake on the apical membrane may occur 
via the ferritin receptor (FnR). The FnR has been identified in the placenta by one 
group although further research is needed to validate this finding and its importance 
for placental iron transfer (47). Knowledge in this field is continuing to grow and there 
are possible other novel undiscovered key iron transporters as well as additional 
repetitive iron transporters due to the importance of tightly regulating fetal iron 
transfer. Current research also has yet to elucidate the mechanism by which iron is 
transferred across the syncytiotrophblast cytoplasm from the apical to the basolateral 
side of the placenta. Some researchers have speculated that an unidentified chaperone 
protein may be involved in this transport (48).  Excess iron may also be stored in the 
placenta as ferritin (Ft) and not transported to the fetus to prevent excess stores from 
being accumulated.  Iron is exported out the basal (fetal) STB membrane through 
ferroportin (49;50). Hephaestin or a similar copper oxidase protein is required to 
oxidize iron (Fe
+2
) to be released from the cells as Fe
+3 
for incorporation into fetal 
transferrin (48).  DMT1 and TfR expression have also been found on the placental 
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basal membrane; however their role in transporting iron at this location has not been 
established (45;49). Georgieff et al., have speculated that although the net flux of iron 
is from mother to fetus, that the placenta may also receive iron signals from the fetus 
in response to fetal iron status (45). This may be in parallel to the enterocyte where the 
net flux of iron is from the lumen, although a small amount of iron is also taken up 
from the serum to influence protein expression of iron transport proteins.  
Most information available on placental iron trafficking has focused only on 
mechanisms of non-heme iron uptake. The expression of proteins implicated in heme 
metabolism in the enterocyte have been identified in the placenta: HCP1 (Proton-
coupled folate transporter/Heme carrier protein), BCRP (Breast cancer resistance 
protein), FLVCR (feline leukemia virus receptor C), hemopexin receptor and heme 
oxygenase (23;51-55). However, thus far none have been linked to iron homeostasis in 
the placenta. As previously noted, HCP1 is now believed to function primarily in 
folate transport (23) and may have a similar role in the placenta. BCRP although 
located on the apical membrane has been identified as an iron efflux protein, and 
Jonker et al., have proposed that its role may be in efflux of drugs that have entered 
the placenta back into the maternal circulation as a protective mechanism for the 
developing fetus (56). Heme oxygenase, while involved in heme metabolism in other 
tissues has a number of other functions in the placenta involving placentation, 
hemodynamic control and antioxidant protection (51).  Researchers have yet to 
elucidate a pathway of placental heme iron transport. If following maternal iron 
absorption heme iron joins the common iron pool in the enterocyte and is thereafter 
processed as non-heme iron, there may not be a separate mechanism for fetal heme 
iron transfer in the placenta. In addition, if mechanisms of heme iron transport are 
identified in the placenta it does not necessarily mean that the source of heme iron is 
from the gut, as heme may also be derived from hemolysis or during hemoglobin 
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destruction.  While the mechanisms of non-heme absorption have been studied in great 
detail, iron transport in the placenta remains largely speculative. It has been difficult to 
determine the essentiality of the above placental transport proteins. In a review article 
by Hentze et al., the authors outlined important animal models that have aided in 
understanding iron homeostasis (30). In this review it was interesting to note that 
transferrin receptor-1 and H-ferritin knockout mice are both embryonic lethal, which 
may imply they are essential in regulating placenta iron transport.  It has also been 
difficult to correlate the upregulation of placental iron transport proteins with neonatal 
iron transfer in humans. However, the use of two oral stable isotopes in this study 
allows for the ability to trace heme and non-heme iron transfer in vivo.  
 
II a. Regulation of Placental Fe Transfer  
 The mechanisms and determinates of placental iron transfer (also known as 
neonatal or fetal iron transfer) are largely unknown. Regulation is likely dependent on 
a number of factors including: maternal/neonatal iron status, placental protein 
upregulation, IRP activity and hepcidin expression. However, many gaps remain in 
our current knowledge of this intricate system. 
The role of maternal iron status in determining infant iron status has been a 
controversial issue. Previously, the fetus was believed to be a “perfect parasite” and 
capable of extracting essential nutrients from the mother, regardless of maternal iron 
status. This theory has been supported by research findings where there has been no 
significant relationship between mild or moderate maternal anemia and infant iron 
status (57-60). Research into this relationship often relied only on measures of 
hemoglobin or hematocrit. Multiple iron status indicators are now available and more 
robust measures may identify deficits in storage iron pools. The other constraint is that 
most studies are only capable of sampling circulating iron stores and subtle deficits in 
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the brain, myelination or other storage sites of iron may not be measurable. However, 
now there is a growing consensus among researchers that maternal anemia does in fact 
impact the iron endowment at birth (61-64) and into the first 6 months (65;66). 
Maternal iron status has also been shown to influence maternal non-heme iron 
absorption and transfer to the fetus (67).  How the placenta mediates this iron transfer 
under various conditions of maternal iron status is unclear. The placenta may extract 
iron from maternal circulation in proportion to maternal iron status, as a direct linear 
correlation with placenta iron concentration and maternal iron status has been 
illustrated (68).  However, the research is not conclusive as other researchers have 
found no correlation between maternal iron status (Hb, TfR, Ft) and placental iron 
concentration or expression of transferrin receptor and ferritin (69).  
Increased expression of placental iron proteins may serve as a compensatory 
mechanism to increase fetal iron transfer under conditions of iron insufficiency. Under 
iron replete conditions the placenta may also accumulate iron as ferritin which serves 
as an iron storage pool to protect the fetus against iron overload (70).  However, there 
are limits in the placenta’s ability to upregulate transport mechanisms as needed and 
several human conditions are known to be associated with alterations in iron stores. In 
diabetic women, despite a demonstrated increase in placental transferrin receptor 
mRNA expression infants were still born with abnormally low iron stores (as defined 
as cord serum ferritin concentrations less than 60 ng/ml) (71).  Likewise, increased 
placental transferrin expression has been demonstrated in abnormal pregnancies (drug 
abuse, pregnancy-induced hypertension, and gestational diabetes) compared to normal 
pregnancies perhaps in response to altered fetal demands, although iron status 
measures were not reported (72). In animal models the expression of both TfR and the 
IRE-regulated form of DMT1 have been shown to increase in response to conditions 
of maternal iron deficiency (50). 
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Ferroportin is developmentally regulated in the placenta and mRNA levels are 
the highest in the third trimester of pregnancy when fetal iron transport is at its peak 
(73). Research using BeWo cells, a placental carcinoma cell line, has found that 
ferroportin expression was not changed in response to iron deficiency, however, 
copper oxidase activity was increased and allowed for increased iron transfer (50). 
Currently it is unclear whether the copper oxidase identified in the placenta is in fact 
hephaestin, or a similar ferroxidase. Whether the expression of ferroportin and 
hephaesin/Cu oxidase are altered in the human placenta in response to both maternal 
and fetal iron status has not been well established. The role of HFE (Human 
hemochromatosis protein) in placental iron transfer is also unclear. In the enterocyte, 
HFE is associated with TfR in the crypt cell and is proposed to be involved in the 
regulation and uptake of transferrin-bound iron in response to body iron stores and aid 
in the programming of key iron transport proteins (74). Although, HFE’s primary role 
may not be in programming but rather in modulating the expression of hepcidin (75).  
Previous research has found HFE to be expressed in the apical plasma membrane of 
the syncytiotrophoblast (STB) cells and associated with TfR (76). This suggests that 
HFE could function in regulating the transfer of maternal iron to the fetus in the 
placenta. However, more recent data has found HFE localized on the basal STB (49). 
On the basal STB HFE was co-localized with ferroportin. In contrast to previous 
research, there was only a minimal association between TfR and HFE. In addition, the 
amount of HFE expressed varied with samples, which could suggest differential 
protein expression due to maternal/fetal iron status; however this was not directly 
addressed in the research and warrants further review. To date, no information exists 
on the ability to increase heme iron transport to the fetus. In addition, the degree to 
which iron transfer can be upregulated is still unclear and the key determinates of 
placental protein expression have yet to be fully elucidated in vivo.  
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Similar to the enterocyte, placental iron transport may also be influenced by the 
IRE/IRP regulatory system. Neonatal iron status (as measured by cord serum ferritin) 
has been found to be inversely correlated to both placental IRP-1 and IRP-2 and 
placental ferritin was likewise correlated with IRP-1 (77). However, in this study 
protein expression of placental TfR and FP-1 were not related to IRP-1, IRP-2 activity 
or neonatal/placental iron status. The lack of a relationship with placental iron 
transporters may be the result of a narrow range of iron status.  In contrast, other 
studies have shown that placental IRP-1 activity is directly related to TfR mRNA 
concentration in human placenta (71). Additional research is needed to clarify the role 
of IRP activity in fetal iron transfer.  
The role of hepcidin in regulating placental iron efflux is largely unknown.  As 
previous described, hepcidin is a negative regulator of iron homeostasis.  Hepcidin 
functions by degrading ferroportin which decreases serosal iron transfer in the 
enterocyte, inhibits the release of iron in macrophages, and blocks placental transport 
(78). In studies with transgenic mice over expressing hepcidin, mice died shortly after 
birth due to severe iron deficiency (79). In addition, in pregnant rats hepatic hepcidin 
mRNA was found to progressively decrease with gestation (80). This corresponded 
with increased expression of intestinal iron transporters (DMT1, DCYTB & FP-1) 
which may help explain the greater fetal iron flux during the third trimester of 
pregnancy. However, hepcidin expression has not been studied in relationship to iron 
absorption and fetal iron transfer during human pregnancy and this may provide key 
information on regulation of iron homeostasis.  
 
III. Assessment of Iron Status 
There are three primary stages of iron deficiency; iron depletion, iron deficient 
erythropoiesis and iron deficiency anemia which correspond to alterations in storage 
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iron, transport iron and ultimately functional iron. The World Health Organization 
recommends the use of multiple indicators to assess iron deficiency and advises that 
the best combination of markers may be hemoglobin, serum transferrin receptor and 
serum ferritin or bone-marrow iron in order to reflect the functional impairment, tissue 
avidity for iron and iron storage (81). Serum ferritin was selected due to the ease of 
measurement and cost. Also, bone-marrow biopsy is not an accepted method for 
screening in healthy populations. A basic description of iron status indicators selected 
for this study and their advantages and disadvantages are outlined in Table 1.1. 
Total body iron (TBI) was calculated based on a formula developed using 
serial quantitative phlebotomy data in healthy men and non-pregnant women: (total 
body iron (mg/kg) = -[log (serum transferrin receptor/serum ferritin) – 
2.8229]/0.1207) (82;83).  With this formula, iron stores are expressed with positive 
values and negative values correspond with functional iron deficiency. From the 
phlebotomy experiments, negative values represent the additional amount of iron 
removed after stores were depleted, or in other words, the quantity of iron required 
before iron stores could be restored. Although validation of this equation is not 
possible in pregnant women and neonates, this measure has been utilized to assess iron 
status in pregnant populations (84;85). 
 Normal biomarkers of iron deficiency are difficult to interpret in infants as 
iron absorption and metabolism are not fully developed (86). The assessment of 
newborn iron stores is further complicated due to limited normative data on iron status 
indicators among healthy neonates and lack of well defined cut off values for iron 
deficiency in infancy. In addition, for both adults and infants serum hepcidin 
measurements are not well defined or standardized. 
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Table 1.1 Assessment of Iron Status
1 
 
Iron Status 
Indicator 
Brief Definition Advantage Disadvantage 
Hemoglobin 
(Hb) 
Measure of anemia, 
reflect amount of 
functional iron in body. 
Inexpensive, 
universally 
available, simple 
to measure 
Low sensitivity/ 
specificity, late 
indicator 
Hematocrit 
(Ht) 
Packed cell volume, 
proportional volume of 
RBCs in whole blood. 
Reflect amount of 
functional iron in body. 
Same as Hb Same as Hb 
Serum 
Transferrin 
Receptor 
(TfR) 
Indicator of tissue iron 
availability. Reflects 
balance between cellular 
iron requirements and 
iron supply. 
Quantitative, 
unaffected by 
inflammation 
Lacks 
standardization, 
effected by the 
rate of 
erythropoiesis 
Serum 
ferritin (Ft) 
Storage iron. Reflect total 
body iron stores. 
Quantitative, 
well 
standardized 
Acute phase 
protein, affected 
by inflammation 
and liver disease 
Total Body 
Iron (TBI) 
TBI (mg/kg) = 
 -[log (serum transferrin 
receptor/serum ferritin) – 
2.8229]/0.1207 
Measure of full 
range of iron 
status, validated 
by phlebotomy 
studies in adult 
volunteers 
Same as 
components, 
equations not 
validated in 
pregnant women 
Hepcidin 
Regulator of iron 
homeostasis. 
Production 
diminished when 
iron reserves 
depleted 
Assay methods 
and 
interpretations of 
results are under 
development 
                                                                                                                            1
Adapted from (81;87;88) 
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There is no gold standard for assessing serum hepcidin and it has been difficult 
to access due to its small size (25AA) and unique folding structure. At present there 
are several methods which include, the new serum hepcidin competitive enzyme-
linked immunosorbent assay (89), surface-enhanced laser desorption/ionization time-
of-flight mass spectrometry (SELDI-TOF-MS) (90;91), liquid chromatography 
tandem mass spectrometry (92) and the commercially available ELISA for serum 
prohepcidin (93-95). It remains difficult to compare values among studies using 
different methods due to the lack of standardization and further research is needed to 
validate each of these methods. Furthermore, data analysis and interpretation are 
complicated by the fact that iron deficiency decreases serum hepcidin often to levels 
below the limit of detection. 
Despite the limitations in assessment, the use of the above iron status indicators 
in combination provides meaningful values to compare the relative differences among 
subject participants in our study.  
 
IV. Stable Isotope Methods  
 Stable isotopes provide a valuable tool for examining iron bioavailability and 
metabolism (96). Stable isotopes have been used in clinical research for several decades 
without any significant biological side effects and are considered appropriate for use in 
pregnant women and children (97;98). Iron stable isotopes are non-radioactive forms of 
iron that are naturally found in fixed amounts in our body and in the environment. Iron 
in nature is comprised of 4 stable isotopes 
54
Fe, 
56
Fe, 
57
Fe and 
58
Fe.  Three of these 
forms of iron (
58
Fe and 
57
Fe and 
54
Fe) are found at very low levels in our environment 
(0.287%, 2.14% and 5.8% respectively) and enriched sources of these stable isotopes 
can be utilized to trace maternal iron absorption and placental iron transfer. Since the 
majority (80-90%) of newly absorbed iron is taken up by red blood cells (RBC) for 
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hemoglobin synthesis, iron absorption can be assessed by determining the fraction of the 
isotope that is incorporated into red blood cells. The use of magnetic sector thermal 
ionization mass spectrometry (TIMS) enables the precise measurements of isotopic 
ratios. In brief, iron is isolated from the blood samples and dried onto rhenium 
filaments. The filaments are heated slowly leading to the evaporation and ionization of 
the iron. The ionized atoms are then mass-separated by an electromagnet (the lighter 
isotopes are deflected more and the heavier isotopes are deflected less). The separate 
beams for each isotope are collected in Faraday cups that convert the ion beam into a 
measurable voltage whose output is tracked and quantified using computer programs. A 
ratio is made between each administered iron isotope and another iron isotope that has 
not been given (
56
Fe). Calculations are adjusted for isotopic fractionation by correcting 
measured voltages to the expected ratio of two non-administered iron isotopes 
(
54
Fe/
56
Fe). Fractionation refers to the tendency of lighter isotopes to evaporate from 
filaments at faster rates than heavier isotopes and is automatically corrected for by the 
specialized computer program that provides the normalized isotopic ratios of the 
samples. The degree to which the normally occurring amounts of these isotopes in the 
body are altered following dosing can then be utilized to determine iron absorption. 
Relative standard deviations using this method average 0.015% and 0.16% for the 
57/56
Fe and 
58/56
Fe ratios, respectively. Detailed calculations are discussed in further 
detail in the methods section.  
Common methods for administering stable iron isotopes include dosing with 
one or two oral isotopes or one oral and one intravenous (IV) isotope. The use of an 
IV tracer allows for the measurement of red blood cell (RBC) incorporation directly. 
When two oral isotopes are used estimates of RBC iron incorporation must be used. 
Common estimates are 80% for adults and 80- 90% for children and these estimates 
are very stable in healthy populations (99). During pregnancy this estimation leads to 
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more uncertainties as RBC iron incorporation is significantly more variable during 
pregnancy due to increases in the size of the intravenous distribution pool and other 
physiologic changes of pregnancy. The magnitude of RBC iron incorporation during 
pregnancy has been found to be affected by iron supplementation and maternal iron 
status (serum ferritin) (13). A limitation of our current study is that we will not use an 
IV tracer. However, since this is a constant factor in our estimates it will not impact 
relative differences between measurement of heme and non-heme iron absorption or 
transfer.  
Although the use of one oral and one IV tracer has advantages a limitation with 
this approach is that iron absorption may only be determined from one iron source. 
The use of two oral tracers enables comparisons in the bioavailability of two iron 
sources. Each subject serves as their own control and differences in RBC iron 
incorporation should cancel out in the same subject. It is not possible to give two oral 
tracers and one IV tracer as two non-enriched isotopes are necessary to correct for 
fractionation. 
 Oral stable isotopes can be used as either intrinsic or extrinsic labels to 
measure nutrient absorption (100).  An intrinsic label involves the biological 
incorporation of the isotope into the food administered. Extrinsic labeling involves 
mixing the stable isotope with the food before consumption, based on the assumption 
that the tracer and the native inorganic element will be absorbed and metabolized in 
the same fashion. Research by Cook et al., has validated the use of extrinsic tags for 
several foods and found highly consistent non-heme iron absorption values from foods 
such as maize, black bean, and wheat studied with either extrinsic or intrinsic labeling 
(101).  
Heme iron on the other hand, is absorbed through a separate pathway than non-
heme iron and is best examined with an intrinsically labeled tracer. Until recently, 
 25 
 
stable isotope techniques for determining heme iron absorption had not been 
developed and only radioisotopes had been utilized (102). To determine heme iron 
absorption, several studies have injected radioactive iron (
59
Fe  or 
55
Fe) into anemic 
rabbits to create biosynthetically labeled rabbit hemoglobin (103-106), while others 
have used radio-labeled animal tissue or a combination of radio-labeled hemoglobin 
and/or animal tissue (107). Martínez-Torrez et al. intravenously injected 
55
Fe into 3-
month old calves and found that most of the total radioactivity (95%) in veal muscle 
was present as heme compounds (hemoglobin and myoglobin) (107). Thus either the 
red blood cells or muscle tissue of intrinsically labeled animals may be fed to humans 
to examine heme iron absorption. While these radioisotope studies have provided key 
information on heme metabolism, due to the risks involved with radioisotopes during 
pregnancy they cannot be applied to investigate human iron transfer to the fetus (108). 
Etcheverry et al. developed a method to successfully infuse stable iron isotopes (
58
Fe) 
into an anemic calf to produce enriched RBCs which could then be used to trace heme 
iron absorption safely in children (102). Working in collaboration with this research 
group we will use a modified version of their method. This research project is the first 
study to utilize intrinsically labeled meat and red blood cells to examine heme iron 
absorption and fetal iron transfer during pregnancy. 
 
Rationale and Summary  
In summary, while non-heme iron metabolism in the enterocyte has been well 
established, the pathway of placental non-heme and heme iron absorption remains 
largely unknown. In addition, the mechanisms and determinates of placental iron 
transfer remain uncertain.  The placental proteins and mechanisms involved in the 
regulation of these proteins have not been well characterized. It has been difficult to 
correlate these processes with transfer of iron to the neonate in vivo in humans due to 
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the lack of suitable methods.  Dual stable iron isotopes allow for simultaneous 
tracking of heme and non-heme utilization so the differential determinants of each can 
be characterized. By following the enrichment of stable iron isotopes, in vivo heme 
and non-heme maternal iron absorption and partitioning of heme and non-heme iron to 
the neonate can be examined in relation to maternal and neonatal iron status and serum 
hepcidin. These data provide novel information on the dynamics of iron metabolism 
during pregnancy and in non-pregnant women of childbearing age.  
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CHAPTER 2 
 
SERUM HEPCIDIN IS SIGNIFICANTLY ASSOCIATED WITH IRON 
ABSORPTION FROM FOOD AND SUPPLEMENTAL SOURCES IN 
HEALTHY YOUNG WOMEN* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Young MF, Glahn RP, Ariza-Nieto M, Inglis J, Westerman M, O'Brien KO. 
Serum hepcidin is significantly associated with iron absorption from food and 
supplemental sources in healthy young women. Am J Clin Nutr 2009;89:533-8. 
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Abstract 
Background: Hepcidin is a key regulator of iron homeostasis but to date no studies 
have examined the impact of hepcidin on iron absorption in humans.      
Objective: To assess relationships between both serum hepcidin and serum 
prohepcidin with non-heme iron absorption assessed in the presence and absence of 
food using dual stable iron isotope techniques. 
Design: The study group included 18 healthy, non-pregnant women. Women received 
in random order: a supplemental iron source ( 8.5 mg of ferrous sulfate containing 0.9 
mg of 
58
Fe as ferrous sulfate) and 6.8 mg of 
57
Fe ferrous sulfate tracer administered 
with a non-heme food source (orange fleshed sweet potato; OFSP: 1.4 mg native iron).  
Iron absorption was determined by analyzing blood samples taken 14 days after 
dosing using magnetic sector thermal ionization mass spectrometry. Serum hepcidin 
was assessed by a new competitive serum enzyme-linked immunosorbent assay 
specific for the refolded, mature 25 amino acid form and serum prohepcidin was 
assessed by an ELISA specific for amino acids 28-47 of the hepcidin prohormone. 
Results: In these women iron absorption averaged 14.71  10.7% from the 
supplemental iron compared to 3.63  6.5% from the OFSP. Absorption of non-heme 
iron assessed in the presence (p = 0.038, r
2
= 0.241) d absence of food (p = 0.0296, r
2
= 
0.263) was significantly associated with serum hepcidin but was not significantly 
related to serum prohepcidin. 
Conclusions: Serum hepcidin, but not prohepcidin, was inversely associated with iron 
absorption from supplemental and food based non-heme iron sources in iron replete 
healthy adult females. 
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Introduction 
Hepcidin has recently emerged as a key regulator of iron homeostasis (1). This 
protein is a small cysteine rich peptide hormone produced in the liver and is 
measurable in human urine (2) and plasma (3). Hepcidin is believed to impact iron 
metabolism via regulation of iron absorption in the gut; iron recycling from 
macrophages; control of hepatic iron storage and this hormone also appears to regulate 
iron transfer through the placental syncytiotrophoblast during pregnancy (1). In the 
enterocyte, hepcidin binds to the basolateral iron export protein, ferroportin, initiating 
its internalization and degradation, effectively blocking iron flux from the cell and 
reducing iron absorption (4).  Over expression of hepcidin has been associated with 
anemia of inflammation (5;6) and severe iron deficiency anemia in transgenic mice 
(7). On the other hand, considerably reduced hepcidin expression occurs in patients 
with hereditary hemochromatosis (8;9). 
Although hepcidin expression has been found to be inversely associated with 
iron absorption and expression of iron transport proteins in rats (10), to date a 
significant relationship between hepcidin expression and iron absorption in humans 
has not been established. This has been in part due to the small size of this protein (25 
amino acids, AA) and the inherent difficulties associated with its measurement. This 
has led some researchers to measure prohepcidin, a linear 60-AA precursor to the 
mature, refolded, 25-AA peptide containing four disulfide bonds. At present the 
validity of using prohepcidin as an index of hepcidin expression has been questioned 
due to the inability to find an association between prohepcidin and iron absorption 
(11;12). 
The objective of this study was to assess relationships between serum 
prohepcidin and hepcidin concentrations with iron absorption using dual stable iron 
isotope techniques. A second objective was to compare the strength of these 
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relationships from a food based matrix versus that observed from a supplemental 
source of iron (ferrous sulfate). We hypothesized that iron absorption would be more 
significantly associated with serum hepcidin versus prohepcidin and that the strength 
of these relationships would be higher from supplemental versus food based non-heme 
iron sources. 
 
Subjects and Methods 
Subjects 
Eighteen young women ages 18-32 years were recruited into the study 
beginning in the spring of 2007. Subjects were eligible for the study if they were not 
taking any vitamin or mineral supplements and did not plan to ingest any over the 2-
week study interval. Subjects were also questioned on their previous supplement use 
and none of the subjects had taken supplements for at least one month prior to the 
study. None of the subjects had a history of intestinal or malabsorption problems, 
blood disorders, ulcers, or joint disease and none were taking any prescription 
medications known to impact iron homeostasis.  Informed written consent was 
obtained from each subject and the study was approved by the Institutional Review 
Board of Cornell University.   
 On the morning of the study, fasted subjects were admitted to the Human 
Metabolic Research Unit (HMRU) at Cornell University. Upon arrival, the women’s 
height and weight were taken (in street clothes and without shoes) with the use of a 
stadiometer and calibrated scale. On the first day of the study women were randomized 
to receive either ferrous sulfate alone or combined with a non-heme food based iron 
source (orange fleshed sweet potato - OFSP). The OFSP used for this study were 
shipped from Peru and were baked in the oven at 350° until soft.  Once cooked, the skin 
was removed from the potatoes and they were mixed thoroughly. Individual servings 
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were frozen until use and briefly microwaved before serving.  The non-heme food based 
meal consisted of approximately 240 g of OFSP [Ipomoea batatas (L.) Lam.] to which 
6.8 mg of 
57
Fe tracer as ferrous sulfate was added to obtain a total iron content from the 
potato and tracer of approximately 8.2 mg. The sweet potatoes were served alone and 
only pepper was used for additional flavoring if desired.  The supplemental iron 
consisted of 7.6 mg of ferrous sulfate (0.9 mg of which was 
58
Fe tracer as ferrous 
sulfate).  The supplement was given with 1.5 ml of flavored syrup composed of a liquid 
sugar substitute (Superose, Medina, NY) flavored with two to three drops of orange 
extract (McCormick Hunt Valley, MD) and administered orally by a syringe.  The only 
beverage allowed during consumption of meals was water. 
  Total iron content of each iron load was measured with atomic absorption 
spectrophotometry (AAS, Perkin Elmer Analyst 800, Norwalk, CT). Calcium content of 
the OFSP was measured using a coupled argon plasma emission spectrometer (ICP-ES) 
(ICAP
 
Model 61E Trace Analyzer, Thermo Jarrell Ash Corporation, Waltham,
 
MA). 
 After consuming each food, subjects remained in the HMRU for the following 
two hours before being fed a light snack (granola bar) then after an additional two hours 
subjects consumed a standardized lunch (vegetable soup, pretzels, and water). The 
following day the women came back to the HMRU at the same time and the study was 
repeated using the second of the randomized foods and following the same study design 
and snack and lunch meals.  Two weeks after the second iron tracer dose was ingested 
the subjects returned to the HMRU and a 7.5 ml venous plasma and 7.5 ml venous 
serum sample were obtained.  
 
Laboratory Analysis  
Serum ferritin was measured by a commercially available enzyme 
immunoassay procedure (Ramco Laboratories, Inc Stafford Texas). Serum soluble 
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transferrin receptors (TfR) were measured with an enzyme linked immunosorbent 
assay (Ramco Laboratories, Inc Stafford Texas). Total body iron was calculated by the 
ratio of serum transferrin receptor to serum ferritin as described by Cook et al.; (total 
body iron (mg/kg) = -[log (serum transferrin receptor/serum ferritin) – 
2.8229]/0.1207) (13).  Hemoglobin was analyzed using a HemoCue (Lake Forest, 
CA). Serum folate, vitamin B12 and C-reactive protein (CRP) were measured using the 
Immulite
®
1000 immunoassay system (Tarrytown, NY). Serum prohepcidin was 
measured by a solid phase enzyme-linked immunosorbent assay with antibodies 
specific for peptides 28-47 of the hepcidin prohormone molecule (DRG International 
Inc., Mountainside NJ). Blinded serum samples were analyzed by Intrinsic Life 
Sciences to measure serum hepcidin (Intrinsic Life Sciences, La Jolla California) 
using a newly developed competitive serum enzyme-linked immunosorbent assay (C-
ELISA) specific for the mature peptide. Detailed methods for the performance of this 
assay have recently been published (14). Using this method; typical intra-assay 
precision and inter-assay coefficients of variations achieved are 5-19% and 12% 
respectively. Moreover, this assay has also been shown to appropriately reflect 
alterations in iron homeostasis (14).  
 
Isotope preparation and sample analysis 
 Iron isotopes (
57
Fe at 88% enrichment and 
58
Fe at 93% enrichment) were 
purchased as the metal from Trace Sciences International (Ontario, Canada).  Both oral 
tracers were converted into sterile, pyrogen-free solution of ferrous sulfate by Anazao 
Health Corporation (Tampa, FL). The isotopic composition of the tracer solutions was 
validated using a Thermoquest Triton TI Magnetic Sector Thermal Ionization Mass 
Spectrometer (Breman, Germany). Whole blood samples (0.5 mL) were digested with 4 
mL concentrated Ultrex nitric acid in a Teflon beaker. Samples were then dried down 
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overnight on a hotplate at 80°C and redissolved in 7 M ultrapure hydrochloric acid 
(HCl) (Ultrex II; J.T. Baker, Phillipsburg, NJ). Iron was extracted using a modified 
anion exchange chromatography method based on that previously described (15;16). 
Small plastic columns were filled with anion exchange resin (AG 1-X8, Bio-Rad 
Laboratories, Hercules, CA) in deionized (DI) water. The column was washed with the 
following sequence:  twice with DI water, once with 0.5 M ultrapure HCl, twice with DI 
water, and four times with 7 M ultrapure HCl. Digested blood samples in 7 M ultrapure 
HCl solution were then added to the column and 7 M ultrapure HCl was added drop 
wise to the columns before collecting the eluted iron with the drop wise addition of 0.5 
M ultrapure HCl. The iron samples were dried on the hot plate and were reconstituted in 
50 μL of 3% HNO3. 
  Extracted iron samples (8 μL) were loaded onto a rhenium filament (H. Cross 
Company Weehawken, NY) with 4 μL of silica gel (Sigma-Aldrich, Inc., St. Louis, 
MO) and 4 μL of phosphoric acid (0.7 N).  Isotopic ratios of 57/56Fe and 58/56Fe were 
measured and ratios were normalized to the 
54/56
Fe ratio. The fractional abundance 
values utilized were 0.02317 for 
57
Fe and 0.00308 for 
58
Fe. Relative standard deviations 
obtained averaged 0.015% and 0.16% respectively for the 
57/56
Fe and 
58/56
Fe ratios, 
respectively. 
 
Calculations 
Iron absorption was calculated using previously described methods (17;18). 
The quantity of 
57
Fe and 
58
Fe incorporated into erythrocytes (Fe inc) was determined by 
enrichment and total circulating iron (Fecirc) which was estimated by using a mean 
blood volume for women (70 mL/kg), the concentration of iron in the hemoglobin 
(3.47 g/kg), the subjects’ hemoglobin value (g/L) and weight (kg). The final 
calculation for iron absorption was determined based on the assumption that 80% of 
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the absorbed isotope was incorporated into erythrocytes. An additional correction 
factor was also used in the analysis to take into account the small amount of 
58
Fe in the 
57
Fe tracer (18). 
 
Data analysis 
All statistical analyses were completed using the STATVIEW 5.0.1 software 
program (Abacus Concepts, Berkeley, CA). Paired t-tests were used to determine the 
significance of relationships between the each iron source and iron absorption. Simple 
linear regression analysis was used to determine relationships between iron status 
(serum ferritin, transferrin receptor, total body iron and hemoglobin), iron absorption, 
serum prohepcidin and serum hepcidin. Data distributions were viewed by examining 
the normal quantile plots and histograms of the data and normality was assessed using 
the Goodness-of-fit test (Shapiro Wilk W test) using JMP 7.0 (Cary, NC). Normally 
distributed data are presented as the mean  SD and data not normally distributed 
(
57
Fe absorption, age, serum ferritin, CRP, and serum hepcidin) are presented as the 
geometric mean  SD.  Variables that were not normally distributed (serum hepcidin, 
57
Fe absorption, CRP and serum ferritin) were transformed by using a natural 
logarithm prior to analysis for statistical purposes. Results shown are the non-
transformed data for interpretation purposes. Results were significant if p < 0.05.  
 
Results 
Subject characteristics 
General characteristics of the study subjects are shown in Table 2.1. All 
subjects had folate and B12 status within normal ranges (defined as > 5 ng/ml and > 
200 pg/ml, respectively). Two subjects had elevated CRP values (15 and 12.1 mg/L).   
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Table 2.1   
General characteristics and iron status indicators of the 18 
study participants
 
 
   
Variable  Mean  SD Range 
   
Age (y)
 1
 22.3  3.1 18.0 - 32.0 
   
Weight (kg) 60.2  8.2 47.0 - 78.2 
   
BMI (kg/m
2
) 22.8  2.8 18.6 - 30.3 
   
Hemoglobin (g/dL) 12.6  1.3 11.0 - 15.6 
   
Folate (ng/ml) 18.4   5.5 11.5 - 31.9 
   
Vitamin B-12 (pg/ml) 594.6   255.5 241.0 - 1088.0 
   
C-reactive protein (mg/L)
 1
 0.95  4.4 <0.2 - 15 
   
Serum ferritin (μg/L)1  27.8  34.1 5.7 - 119.7 
   
Serum TfR (mg/L) 4.7  1.3 2.8 - 7.1 
   
Total body iron (mg/kg) 5.05  3.4 -1.5 - 11.7 
   
Serum prohepcidin (μg/L) 47.0  12.9 30.7 - 77.8 
   
Serum hepcidin (μg/L) 1   39.95  69.6 1.5 - 248.5 
            1 
Geometric mean 
 
 50 
However these subjects did not have elevated serum ferritin values, and all serum 
ferritin values were within a normal range reported for healthy young women (19). 
Excluding individuals with elevated CRP from subsequent analyses did not 
significantly alter study results so these subjects were included in all remaining 
analyses. There was a limited range of iron status among these healthy participants 
with the majority being non-anemic, as evidenced by the finding that none had a 
hemoglobin value less than 11 g/dL (the mean hemoglobin value in the group was 
12.6  1.3 g/dL; a value above the cutoff of 12 g/dL used to define anemia in non-
pregnant women); and all subjects had serum transferrin receptor concentrations less 
than 8.5 mg/L, indicating the absence of tissue iron deficiency (20).  Only one of the 
18 subjects had a total body iron level below zero (indicative of depleted iron 
reserves) and this subject also had a serum ferritin concentration <12 μg/L.   There 
was a mean difference of 23 μg/L between the serum ferritin concentrations of 
subjects with Hb concentrations < 12 g/dL compared to those ≥ 12 g/dL (23.9  10.2, 
n = 7 vs. 46.9  41.0, n = 11) although this difference was not statistically significant 
(p = 0.17). Relationships among iron status indicators were examined. From these 
analyses the only significant relationship observed was between serum transferrin 
receptor and the natural log of serum ferritin (r
2
= 0.458, p = 0.002). 
Serum prohepcidin ranged from 30.7 to 77.8 μg/L (47.0  12.9 μg/L) and was 
not significantly correlated with either the natural log of serum ferritin, serum soluble 
transferrin receptor, total body iron, hemoglobin or the natural log of CRP. Moreover, 
no significant relationships were observed between serum prohepcidin and the natural 
log of serum hepcidin (p = 0.93).  Serum hepcidin ranged from 1.5 to 248.5 μg/L 
(39.95  69.6 μg/L). The natural log of serum hepcidin was significantly associated 
with the natural log of CRP concentration (p = 0.009). This relationship held even 
when the two subjects with elevated CRP were excluded from the analysis (p = 0.009). 
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The natural log of serum hepcidin was not significantly correlated with BMI or 
measures of iron status (natural log of serum ferritin, serum soluble transferrin 
receptor, total body iron or hemoglobin).  
 
Iron absorption  
 Iron absorption from ferrous sulfate administered in the fasted state was 
significantly greater than that measured in combination with a non-heme food based 
iron source (p = 0.0006, mean difference of 8.97%). No significant differences in iron 
absorption were found as a consequence of the order of feeding OFSP versus 
supplemental iron alone.  Women absorbed an average of 14.71  10.7% (0.58 - 
43.9%) from the 
58
Fe -ferrous sulfate compared to 3.63  6.5% (1.4 - 22.1%) from the 
OFSP (non-heme food source) labeled with 
57
Fe. The intrinsic iron content of the 
OFSP variety used in this study was 6.153 μg/g    0.6 (n = 5) and the calcium content 
of the OFSP was 304  21 μg/g (n = 3).  Due to environmental, genotypic and other 
factors, iron concentration in OFSP can vary widely but the iron content of the OFSP 
we used is comparable to that reported from a similar source (9 μg/g) using earlier 
data from the Food and Agriculture Organization (21).  
 Despite the limited number of iron deficient subjects there were inverse non-
significant trends between the natural log of serum ferritin and absorption of ferrous 
sulfate (p = 0.08) and between natural log of serum ferritin and the natural log of iron 
absorption from the OFSP (p = 0.12). The exclusion of the two subjects with elevated 
CRP from these analyses did not change the significance of the relationship (p = 0.09, 
p = 0.13, respectively). The natural log of serum hepcidin was significantly correlated 
with both the absorption of supplemental ferrous sulfate given alone (p = 0.0296) or 
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from the natural log of iron absorption when tested in the presence of the OFSP (p = 
0.038), Figure 2.1.  This relationship also remained significant when the two subjects 
with elevated CRP were excluded from the analysis (p = 0.028, p = 0.011, 
respectively).  
In contrast, serum prohepcidin was not significantly correlated with iron 
absorption from the ferrous sulfate administered alone (p = 0.776) or in combination 
with OFSP (p = 0.429) tested as the natural log of iron absorption from OFSP. Other 
iron status indicators including total body iron, serum transferrin receptor and 
hemoglobin were not significantly related to iron absorption from ferrous sulfate 
administered alone or in combination with OFSP. 
 
Discussion 
This study adds to the growing body of literature affirming the role of hepcidin 
as a key iron regulatory hormone and to our knowledge is the first study to assess the 
relationship between this 25-AA hormone and measures of iron absorption in humans.  
Using this approach, iron absorption from ferrous sulfate administered to fasted 
subjects alone or in combination with a non-heme food source were both inversely 
associated with the mature 25-AA form of serum hepcidin in healthy young women. 
In contrast, iron absorption from the food based or supplemental iron source used in 
this study was unrelated to serum prohepcidin, a finding that is similar to other non-
significant associations published in the literature (11;12). Hepcidin is initially 
synthesized as a linear 84-AA preprohepcidin protein containing a putative 24-AA 
signal sequence, a 35-AA pro-region and a 25-AA active hepcidin peptide (1).  
Research by Valore et al., illustrates that the precursor protein undergoes two 
cleavages, first the signal sequence is lost and then the pro-region is cleaved by the 
hepatic prohoromone convertase furin (22).  
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Figure 2.1 Non-heme Iron Absorption and Serum Hepcidin. 
 In a group of eighteen healthy non-pregnant women iron absorption was assessed in 
blood samples collected 2 weeks post-dosing with 
58
Fe (as ferrous sulfate) and 
57
Fe 
(added extrinsically to a meal of orange fleshed sweet potato-OFSP).  Serum hepcidin 
was significantly inversely related with both iron absorption from the 
58
Fe labeled 
ferrous sulfate; p = 0.0296, y = 31.781 – 4.628x, r2= 0.263, n = 18 and with iron 
absorption from the 
57
Fe meal of OFSP; p = 0.038, y = 2.697 – 0.381x, r2= 0.241, n = 
18. A second axis has been added to the figures for interpretation purposes of 
transformed data.
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In addition, there appears to be no consistent ratio or relationship between the 
refolded, mature form of hepcidin and prohepcidin concentrations and factors that 
impact hepcidin such as iron and hypoxia have no response on the cleavage of 
prohepcidin (22). In the present study, serum prohepcidin ranged from 30.7 - 77.8 
μg/L which is a lower range than previously reported in healthy individuals by Hadely 
et al. (99 - 376 μg/L, n= 28 women) (11) and by Kulaksiz et al. (51.6 - 153.4 μg/L, n= 
26 men and women) using the same approach (23).  We found no significant 
relationships between serum prohepcidin, iron absorption or related indicators of iron 
status. This is consistent with previous research by Roe et al., that reported no 
significant association between prohepcidin and iron stores nor did these 
concentrations differ between pregnant women, patients with hereditary 
hemochromatosis and healthy men (12).  In a similar population of healthy non-
pregnant women, no significant relationships between iron absorption and serum or 
urinary prohepcidin were observed, leading the authors to propose that serum 
prohepcidin may not reflect the refolded, active form of hepcidin responsible for 
regulating iron absorption (11).  
Serum hepcidin in these women ranged from 1.50 - 248.5 μg/L and was 
predominately within previously reported 5
th
 - 95
th
 percentile serum hepcidin ranges in 
men (29-254 ug/L) and women (17-286 ug/L) using the same serum ELISA (14). 
However, in other reports using liquid chromatography tandem mass spectrometry a 
much lower range of serum hepcidin was reported in healthy men (< 1.0 – 19.8 μg/L) 
and women (1.5- 45.6 μg/L) (24).  Serum hepcidin was significantly associated with 
iron absorption in our study population. From limited data available at present; a 10 
fold lower serum hepcidin concentration has been reported in anemic versus non-
anemic individuals (25). Using our observed relationship between hepcidin and iron 
absorption, a 10 fold decrease in the mean serum hepcidin (from 66.7 to 6.67 μg/L) 
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would be expected to increase iron absorption by approximately 2 fold; i.e  from 
12.34% to 23% for ferrous sulfate alone and from 3.0% to 7.2% when administered 
with the OFSP source as fed in this study. However, this interpretation is limited by 
our small sample size and narrow iron status range. Further research is needed to 
understand the relationship between serum hepcidin and non-heme iron absorption in 
different population groups with a wider range of iron status in order to better 
characterize this relationship. Since this finding was reported other studies have 
replicated these data and reported a similar relationship between hepcidin and non-
heme iron absorption (26;27). 
No significant relationships between hepcidin and other measured indicators of iron 
status (serum ferritin, total body iron, serum transferrin receptor or hemoglobin) were 
observed in the current study.  This finding may be due in part to the small sample size 
and limited number of iron deficient study participants.  In other published data serum 
hepcidin was significantly related to serum ferritin but not to hemoglobin, serum iron, 
or serum transferrin receptor (28).  In the current study serum hepcidin was directly 
associated with CRP. Two subjects had elevated CRP which may be in response to 
recent infection or inflammation; however all findings remained significant with or 
without the inclusion of these two subjects. 
Iron absorption from the iron supplement (14.71%) was significantly higher 
when given without additional non-heme iron as OFSP (geometric mean 3.63, mean 
5.75%). Our value of iron absorption from an 8 mg dose of ferrous sulfate was similar 
to that reported for ferrous sulfate (60 mg) by Olivares et al., in women who were 
studied before and after iron supplementation (9.7% and 12.5%, after adjustment to a 
reference dose) (29). Our value of iron absorption studied in the presence of OFSP  is 
comparable to that reported in a group of iron replete women with similar ferritin 
status (6.26% and 42.6 μg/L, respectively) (30).  The lower iron absorption from the 
 57 
OFSP meal relative to iron supplement is likely due to the presence of the food matrix, 
as the components of the OFSP may affect solubility, gastric pH and absorption.  
OFSP was selected as the non-heme iron source due to the importance of this 
staple crop in many areas of world. HarvestPlus has identified the sweet potato as one 
the six target crops for biofortification based on its potential to help alleviate 
micronutrient deficiencies in developing countries (31). In particular the OFSP is a 
rich source of β-carotene (32) and has been proven effective in improving vitamin A 
status in children (33;34). Although the iron content in OFSP is relatively low 
compared to animal food sources, due to its widespread daily consumption it may help 
contribute to daily iron needs. In this study a 240 g serving of this vegetable would 
provide approximately 0.1 mg of absorbable iron which corresponds to almost 7% of 
the estimated average daily amount of absorbed iron required (1.5 mg) by non 
pregnant women (35). However, it is important to note that these results were obtained 
from a single meal comprised only of OFSP and additional dietary factors ingested 
from a mixed meal may influence its bioavailability. In addition, the amount of 
57
Fe 
required to trace iron absorption from this meal is considerably higher than the iron 
load that would be ingested by a meal containing only OFSP. Intrinsic labeling 
techniques or multiple additions of smaller iron tracer doses on subsequent days would 
be needed to more precisely assess iron bioavailability from this food source.  
At present there are multiple methods that can be utilized to measure hepcidin 
and prohepcidin. A commercially available ELISA is available to measure prohepcidin 
in urine and serum samples (11;12;36). In addition to the competitive serum ELISA 
utilized for this study, hepcidin can also be measured by surface-enhanced laser 
desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) (25;37), 
liquid chromatography tandem mass spectrometry (LC-MSMS) (24) and a laboratory 
developed immunodot assay for urinary hepcidin (5). SELDI-TOF-MS and LC-
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MSMS have limitations on equipment expense and availability and SELDI-TOF-MS 
also has limited analytic sensitivity and ability detect low levels of serum hepcidin 
(37). Interpretation of the values reported to date are confounded by the different 
ranges reported in these techniques and the lack of a reference material to allow for 
standardization of values obtained between analytical approaches and laboratories.   
Iron deficiency remains the most common nutrient deficiency in the world 
(38). Deficiency of this mineral is increasingly recognized to have long-term and 
irreversible effects during key life stages including fetal development, early childhood 
and pregnancy (39).  In spite of the importance of this nutrient many key aspects of its 
regulation are unanswered. These data generated using a new immunoassay, specific 
for the mature, bioactive form of hepcidin, present novel findings on the inverse 
relationship between serum hepcidin and iron absorption from non-heme iron 
administered as a supplement with or without the presence of a non-heme food iron 
source in a group of healthy non-pregnant women. Due to the role of iron in human 
health, continued research on the role of hepcidin and its impact on whole body iron 
kinetics of both heme and non-heme iron are needed in relation to age, physiological 
state and iron status.
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CHAPTER 3 
 
SERUM HEPCIDIN IS NEGATIVELY ASSOCIATED WITH NON-HEME 
IRON ABSORPTION AND UNRELATED TO HEME IRON ABSORPTION IN 
PREGNANT AND NON-PREGNANT WOMEN
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Abstract  
Background: Heme iron absorption during pregnancy remains largely unexplored and 
the role of hepcidin in regulating dietary heme iron absorption is unknown.  
Objective: The objective of this research was to examine the impact of hepcidin on 
heme and non-heme iron absorption.  
Design: This study was undertaken in a group of 18 pregnant women (ages 16-32 y; 
week 32-35 of gestation) and 11 non-pregnant women (ages 18-27 y). Fasted subjects 
were randomly assigned to receive both a heme meal (intrinsically labeled 
58
Fe pork) 
and labeled ferrous sulfate (
57
Fe) fed on alternate days. Blood samples obtained two 
weeks post-dosing were used for assessment of red blood cell incorporation of iron 
isotopes, iron status and serum hepcidin. 
Results: Heme iron absorption was significantly greater than non-heme iron 
absorption in both pregnant (47.7  14.4 vs. 40.4  13.2%) and non-pregnant subjects 
(50.1 14.8 vs. 15.3  9.7%). During the third trimester of pregnancy absorption of 
non-heme iron was significantly associated with measures of iron status (transferrin 
receptor (p = 0.003), total body iron (p = 0.02), and hemoglobin (p = 0.04)). In 
contrast, heme iron absorption was not influenced by maternal iron stores but was 
inversely associated with age (p = 0.02). Hepcidin was significantly inversely 
associated with non-heme iron absorption (p = 0.04), but had no significant impact on 
heme iron absorption in either pregnant or non-pregnant subjects.  
Conclusion: Our study suggests that absorption of heme iron from animal based foods 
provides a highly bioavailable source of dietary iron during pregnancy that is not 
substantially affected by hepcidin concentrations or iron stores.  
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Introduction 
Iron (Fe) deficiency is a public health problem affecting 1.62 billion people 
globally, with pregnant women being at increased risk (1). Anemia is associated with 
labor/delivery complications, preterm delivery, low birth weight, reduced infant Fe 
status, impaired mother-child interactions and increased infant and maternal mortality 
(2-4). Due to the adverse outcomes of maternal Fe deficiency, an understanding of 
dietary Fe bioavailability from all dietary iron sources is vital. These data will help 
inform the development of public health programs and nutritional recommendations. 
Dietary Fe is obtained from non-heme (mostly plant-based) and heme (mostly animal 
based) sources. While details of non-heme Fe absorption are largely known, 
mechanisms of heme Fe absorption remain elusive (5). In non-pregnant women, heme 
Fe absorption has been found to be 3-fold higher than that of non-heme Fe absorption 
(6). Non-heme Fe absorption has also been found to be more responsive to alternations 
in body Fe stores in comparison to heme Fe absorption in men (7). The impact of the 
increased Fe demands of pregnancy on heme versus non-heme Fe absorption remains 
unknown and to our knowledge heme Fe absorption has not been assessed during 
pregnancy.  
Hepcidin is a small hormone produced by the liver that is now known to be a 
key regulator of Fe homeostasis (8). This hormone is known to be inversely associated 
with absorption of non-heme Fe in non-pregnant women and men (9;10) as discussed 
in Chapter 2. At present no human data on the role of this hormone on iron absorption 
during pregnancy is currently available. An improved understanding of the role of 
hepcidin concentration on absorption of dietary iron from all sources could potentially 
provide valuable information and therapeutic options for anemic pregnant women.  
Furthermore the degree to which heme Fe absorption is regulated by circulating 
hepcidin concentrations may provide additional insight into heme Fe homeostasis. 
 68 
 
To address these issues we undertook an Fe absorption study using a dual 
stable isotope approach in pregnant and non-pregnant subjects. Iron absorption from 
an intrinsically labeled heme source was compared to labeled ferrous sulfate. We 
hypothesized women would have higher Fe absorption from the heme source, and that 
hepcidin would be associated with both heme and non-heme Fe absorption. 
 
Subjects and Methods 
Twenty non-smoking, pregnant women, ages 16-32 years, were recruited 
between 2008-2009 from the Rochester, NY Strong Midwifery Group and the 
Rochester Adolescent Maternity Program (RAMP). All women were healthy with 
uncomplicated pregnancies at the time of recruitment. Exclusion criteria at entry into 
the study included: gestational diabetes, hypertension, preeclampsia, underlying 
malabsorption diseases and diagnosed medical conditions known to impact Fe 
homeostasis. Informed written consent was obtained from each subject and the study 
was approved by the Institutional Review Board of Cornell University and the 
University of Rochester Research Subjects Review Board. The study was registered 
with clinicaltrials.gov as NCT01019096 (http://www.clinicaltrials.gov).  
Twelve healthy non-smoking, non-pregnant women ages 18-27 years were 
recruited in 2009 from Ithaca, NY. Exclusion criteria included underlying 
malabsorption diseases or diagnosed medical conditions known to impact Fe 
homeostasis. Non-pregnant participants did not consume any supplements for one 
month prior to the study and for the duration of the study. Informed written consent 
was obtained from each subject and the study was approved by the Institutional 
Review Board of Cornell University.   
 Stable iron isotopes were purchased as the metal; 
57
Fe at 94.69% enrichment and 
58
Fe at 93.34% enrichment from Trace Sciences International (Ontario, Canada).   
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The non-heme Fe tracer (
57
Fe) was prepared as ferrous sulfate as a sterile, pyrogen-free 
solution by Anazao Health (Tampa, FL). The Fe tracer (
58
Fe) used for intrinsic labeling 
of heme was prepared as ferrous citrate in our laboratory and was sent to Analytical 
Research Labs (Oklahoma City, OK) for sterility testing. Isotopic composition of tracers 
was validated using Magnetic Sector Thermal Ionization Mass Spectrometry (TIMS) 
(Thermo Scientific Triton TI Thermo Fisher Scientific Inc, Bremen, Germany). The 
heme iron source was prepared by intrinsically labeling (
58
Fe) porcine muscle and red 
blood cells (RBC) at Baylor College of Medicine following previously published 
methods, (11) as approved by the Baylor College of Medicine Institution Animal Care 
and Use Committee. In brief, a 3-day old female piglet was housed in a stainless steel 
stall and fed a diet to induce Fe deficiency (Fe-free sow replacement milk, Research 
Diets, Inc.). Piglets are typically given intramuscular Fe at birth (100-200 mg) to prevent 
Fe deficiency. The standard Fe injection was replaced with two 75 mg doses of 
58
Fe, as 
ferrous citrate. At 28 days of age the piglet was sacrificed at a facility, Texas A&M 
University, approved by the USDA and the State of Texas. The RBCs and muscle (rich 
sources of heme iron) were collected, processed (11),  and used as the intrinsically 
labeled heme Fe source for this study.  Enrichment of 
58
Fe in the muscle and RBCs was 
quantified by TIMS and found to be 18.0 ± 0.80% and 17.3 ± 0.01% (mean ± SD) 
respectively.  
 To accommodate the timing of subject recruitment two batches of the heme Fe 
meal were prepared. In the first batch prepared for the pregnant subjects, enriched 
ground pork (203 grams) and enriched RBCs (3.9 grams) were combined with tomato 
sauce (Hunts, Dallas, TX) and chili seasoning (McCormick, Sparks, MD). Based on 
preliminary results with the pregnant population, a slightly lower 
58
Fe dose from the 
labeled pork meal was used for the non-pregnant subjects in order to dose a larger 
sample population and still achieve adequate enrichment values. Previous research has 
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found no significant difference in iron absorption from meat consumed alone versus 
meat consumed with additional hemoglobin (12). In the second batch of pork prepared 
for the non-pregnant subjects, non-enriched ground pork (198 grams) and enriched 
RBCs (3.5 grams) were combined with tomato sauce and chili seasoning.   The chili 
was well mixed and frozen as individual 320 g servings until use.  Aliquots of both 
heme meal batches were sent to Microbac Laboratories, Inc., (Warrendale, PA) for 
food safety testing and analyzed for total isotopic content by TIMS and total Fe 
content by atomic absorption spectrophotometry (AAS) (PerkinElmer Analyst 800; 
PerkinElmer Inc, Norwalk, CT).  
 Clinical studies in the pregnant participants were undertaken at Strong Memorial 
Hospital’s Clinical and Translational Science Center (CTSC).  Women came to the 
CTSC during the last trimester of pregnancy (gestation 32-35 weeks) on two 
consecutive days with each visit lasting approximately five hours. Subjects were asked 
to discontinue prenatal supplementation for 3 days prior to the study and two days 
following ingestion of each labeled test food. The morning of the first absorption study, 
each woman’s height and weight were recorded with the use of a stadiometer and a 
calibrated scale. Fasted subjects received a standard breakfast (bagel, jelly/butter and 
non-ascorbic acid and non-Fe fortified apple juice) and 2 hours later ingested the Fe test 
meal (intrinsically labeled 
58
Fe pork or 
57
Fe as ferrous sulfate). The serving of 
intrinsically labeled pork provided 0.46 mg of 
58
Fe from pork and 0.46 mg from RBCs 
for a total 
58
Fe dose of 0.92 mg and 7.9 mg total Fe per serving.  The ferrous sulfate 
administered was given as, 8.2 mg of 
57
Fe as ferrous sulfate (total Fe, 8.6 mg) flavored 
with 2 mL of raspberry syrup containing 0.391% ascorbic acid (Humco, Texarkana, 
TX).  Both forms of iron were fed to fasted subjects without other food or liquids. The 
two forms of Fe were fed randomly (coin toss for order) such that half of the women 
received the heme meal on the first day and the ferrous sulfate on the second day with 
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the other women consuming these forms of iron in the reverse order. Each subject 
served as their own control for comparing heme versus non-heme iron absorption. After 
each of the test meals were ingested, women remained in the CTSC for an additional 
two hours before ingesting a standard lunch (chicken noodle soup, apple, and pretzels). 
To minimize the influence of other dietary factors on Fe absorption all women were 
given a standard dinner (chicken, green beans, rice, carrots, ranch dressing, peaches and 
ice cream) and snacks to take home and consume. The pregnant adolescents were asked 
to stay overnight at the CTSC between test meals to minimize transportation difficulties. 
All subjects were asked to consume the same amounts and types of foods on the second 
test day as those ingested on the first day. Subjects returned to the CTSC two weeks 
after the second Fe tracer was ingested in order to collect a 15 mL venous blood sample. 
 Clinical studies in non-pregnant subjects were undertaken at the Human 
Metabolic Research Unit (HMRU) at Cornell University, using the same protocol as 
utilized for the pregnant subjects. The intrinsically labeled pork provided 0.6 mg of 
labeled 
58
Fe RBCs and 9.9 mg of total Fe per serving.  For the non-heme absorption 
study women ingested an 8.2 mg dose of 
57
Fe as ferrous sulfate (total Fe, 8.6 mg) 
flavored with 2 mL of raspberry syrup (Humco, Texarkana, TX). Subjects remained in 
the HMRU for two hours and then were fed a standard lunch.  As in the pregnant cohort, 
dinner and snacks were provided for subjects to take home. Subjects returned to the 
HMRU two weeks post-dosing for the blood draw.  
Hemoglobin and hematocrit were analyzed in blood samples by the Strong 
Memorial Hospital’s clinical laboratory using the Cell Dyn 4000 system (for pregnant 
subjects) and using a Coulter hematology analyzer at the HMRU (for non-pregnant 
subjects).  Whole blood was centrifuged and serum was stored at -80°C until analysis. 
Serum ferritin was measured by a commercially available enzyme immunoassay 
procedure (Ramco Laboratories, Inc Stafford Texas). An indicator of inflammation 
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(C-reactive protein, CRP) was assessed using the Immulite
®
1000 immunoassay 
system (Tarrytown, NY). Serum soluble transferrin receptor (TfR) was measured with 
an enzyme linked immunosorbent assay (ELISA) (Ramco Laboratories, Inc Stafford 
Texas). Total body Fe (TBI) was calculated by the ratio of serum transferrin receptor 
to serum ferritin as described by Cook et al.; (total body Fe (mg/kg) = -[log (serum 
transferrin receptor/serum ferritin) – 2.8229]/0.1207) (13).  Serum folate, vitamin B12 
and erythropoietin were measured using the Immulite
®
1000 immunoassay system 
(Tarrytown, NY). Serum leptin was measured using a commercially available ELISA 
kit (Millipore, Billerica, MA).  Serum samples were sent to Intrinsic Life Sciences for 
analysis of serum hepcidin using a competitive serum enzyme-linked immunosorbent 
assay (C-ELISA) (Intrinsic Life Sciences, La Jolla California).(14). The lower limit of 
detection for this assay is 5 μg/L. 
 To assess iron absorption, whole blood (0.5 mL) was digested and iron was 
extracted using anion exchange chromatography (15). All acid used was ultrapure 
(Ultrex, JT Baker). Iron isotope ratios (
57/56
Fe, 
58/56
Fe and 
54/56
Fe ) were measured 
using TIMS and Fe absorption was determined as described in previous publications 
(15-17). The enrichment of each isotope in RBCs was measured as the degree to 
which the natural abundance ratio in RBC was increased as a result of absorption of 
the stable Fe tracer using the formula; [(
57/56
Fe ratio in sample - 
57/56
Fe natural 
abundance ratio)/ 
57/56
Fe natural abundance ratio] *100. A similar equation was used 
to assess the enrichment of 
58
Fe in RBC from the labeled heme meal. Natural 
abundance (NA) Fe isotopic ratios utilized were 0.02317 for 
57/56
Fe and 0.00307 for 
58/56
Fe.  The total circulating Fe (mg) was estimated using the subjects’ weight (kg), a 
blood volume estimate (65 mL/kg for non-pregnant and 70 mL/kg for pregnant 
subjects), hemoglobin concentration (kg/L) and the concentration of Fe in hemoglobin 
(3.47 g/kg) as reported by Fomon et al.(18). Total Fe incorporated was then calculated 
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using the RBC enrichment, total circulating Fe, the Fe dose administered and the 
natural abundance of isotope given (NA57, 0.0214; NA58, 0.00287). Final values for Fe 
absorption were determined based on the assumption that 80% of the absorbed Fe 
would be incorporated into erythrocytes (19;20). An additional correction factor was 
used in the Fe absorption calculations in order to correct for the small amount of 
58
Fe 
that was contributed by the 
57
Fe tracer (16).  
Data were analyzed using JMP 8.0 (SAS Institute INC, Cary, NC). Linear 
regression analyses were used to examine relationships between Fe status, hepcidin 
and Fe absorption. Paired t-tests were used to compare the differences of relationships 
between heme and non-heme Fe absorption within subject groups. Differences 
between subject groups were compared using a t-test or the Wilcoxon rank sum test 
for nonparametric data. Serum hepcidin concentrations below the limit of detection 
were assigned a value of 2.5 μg/L for data analysis (a value halfway between zero and 
the limit of detection, 5 μg/L). A sample size of 20 pregnant women was selected to 
provide a power of 80% using an alpha level of 0.05 to detect a 4.5% difference in 
iron absorption, allowing for an attrition rate of 20%. Variables were tested for 
normality using goodness-of-fit test and those that were not normally distributed were 
transformed (natural log) prior to statistical testing. Results were analyzed with and 
without the two subjects who developed preeclampsia (PE). The results and p-vales 
are given for the complete sample size unless inclusion of PE subjects impacted the 
significance as noted in the results. Differences were considered significant if p < 
0.05.  
 
Results 
General characteristics of the study subjects are shown in Table 3.1.   
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Table 3.1 
General characteristics of the participants
1,2
 
 
   
Variable  
Pregnant 
 (n = 18) 
Non-Pregnant  
( n = 11) 
   
Age at enrollment (y) 18.5  4.0 
 (16 - 32)
 a
 
21.5  2.4  
(18 - 27)
 b
 
   
BMI (kg/m
2
) at time of study 32.5  6.9  
(23.3 - 46.5)
 a
 
23.0  2.2  
(18.9 - 25.8)
 b
 
   
Pre-pregnancy BMI (kg/m
2
) 25.0  7.1  
(20.7 - 43.6)
 
 
N/A 
   
Gestational Age at Study (wks)
 
 33.4   0.9 
 (32.0 - 34.6)
 
 
N/A 
   
Race   
      African American 50% 0% 
      Caucasian 50% 73% 
      Native American 0% 9% 
      Asian 0% 18% 
   
Ethnicity   
      Hispanic 39% 0% 
      Non-Hispanic  61% 100% 
    
1
All normally distributed values are mean ± SD and all non normally distributed 
values are median ± SD (range in parentheses) 
2
Variables that are significantly different among pregnant and non-pregnant  
subjects are denoted with a different letter (p < 0.05) 
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Of the pregnant subjects enrolled in the study; those under the age of 18 y were 
classified as adolescents (50%) and the remaining 50% were > 19 yrs and were 
classified as adults. Among the pregnant women enrolled, 50% entered pregnancy 
with a normal BMI, 22% were overweight (BMI > 25 kg/m
2
) and 28% were obese 
(BMI > 30 kg/m
2
) prior to pregnancy. None of the pregnant or non-pregnant subjects 
were underweight. Three of the non-pregnant subjects were classified as overweight 
and the remaining nine subjects had a normal BMI. 
Three subjects did not complete the study. One pregnant subject did not 
consume all of the pork meal and was withdrawn from the study. Another pregnant 
adolescent completed the two day study but did not attend the 2-week blood draw 
appointment. One non-pregnant subject did not attend the second day of dosing and 
was withdrawn from the study. The final study population included 18 pregnant and 
11 non-pregnant subjects. Two pregnant study participants (ages 16 and 20) developed 
preeclampsia (PE). In these two women, blood samples were obtained at delivery 
which occurred at 10 days post-dosing in one subject and on day 14 post-dosing in the 
second subject.  Iron status indicators are described in Table 3.2. Among the pregnant 
subjects, 61% had depleted Fe stores (serum ferritin < 20 μg/L) and 22% had negative 
TBI values. The majority (67%) of the pregnant women had non-detectable serum 
hepcidin levels in the third trimester of pregnancy and these subjects were also the 
women with depleted iron stores. All but one of the non-pregnant women were Fe 
replete, with one having mild anemia (Hb = 118 g/L). Only three non-pregnant 
subjects had non-detectable levels of serum hepcidin and they likewise all had serum 
ferritin values near depletion.  None of the pregnant subjects had folate (< 6.8 nmol/L) 
or B-12 deficiency (< 148 pmol/L) (21). All non-pregnant subjects had normal folate 
levels; however one subject had a low B-12 value (111 pmol/L) but was not anemic 
(Hb = 137 g/L). The two subjects with PE had elevated CRP (66.1, 6.1 mg/L). 
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Table 3.2 
Iron status indicators for pregnant and non-pregnant subjects
1,2
 
   
Variable 
Pregnant 
(n = 18) 
Non-Pregnant 
(n = 11) 
Hemoglobin (g/L) 
    ( % Anemic) 
114  9 a 
< 110 g/L:  39% 
130  9 b 
< 120  g/L: 9% 
 
   
Serum ferritin (μg/L) 
    < 12 μg/L (% Fe Deficiency) 
    < 20 μg/L (% Fe Depletion) 
17.5   16.4 a 
22% 
61% 
40.5  23.3 b 
0% 
9% 
   
Serum transferrin receptor (mg/L) 
    > 8.5 mg/L 
6.1  1.5 a 
11% 
4.2  1 b 
0% 
   
Total Body Iron (mg/kg) 
    < 0 mg/kg 
2.3  3.0 a 
22% 
6.0  1.7 b 
0% 
   
Serum hepcidin (μg/L) 2.5  47.8  a 16.7  13.8 b 
   
C-reactive protein (g/L) 3.5  15.1 a 0.66  1.4 b 
   
Folate (nmol/L) 37.9  21.2 a 38.6  6.7 a 
   
Vitamin B-12 (pmol/L) 213.8  113 a 223.6  169.1 a 
   
Erythropoietin  (IU/L) 30.5  18.0 a 12.7  8.7 b 
   
Leptin (μg/L) 40.6  24.5 a 9.8  6.1 b 
1
All normally distributed values are mean ± SD and all non normally distributed 
values are median ± SD 
2
Variables that are significantly different among pregnant and non-pregnant 
subjects are denoted with a different letter (p <0.05) 
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Pregnant women absorbed a significantly greater percentage of Fe from the 
intrinsically labeled pork meal (47.7  14.4%; p = 0.04) in comparison to absorption 
from a similar iron load ingested as ferrous sulfate (40.4  13.2%), Figure 3.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Heme and Non-Heme Iron Absorption.   
Heme (intrinsically labeled 
58
Fe pork) and non-heme (
57
Fe as ferrous sulfate) iron 
absorption was examined in 18 pregnant and 11 non-pregnant subjects. Pregnant and 
non-pregnant subjects had significantly greater heme iron absorption compared to 
non-heme iron absorption (p = 0.04, p< 0.0001). Means that are significantly different               
from each other are denoted with a different letter (p< 0.05). 
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A similar pattern was observed among the non-pregnant women with Fe 
absorption from the intrinsically labeled pork meal (50.1  14.8%) being significantly 
greater than absorption of ferrous sulfate (15.3  9.7%, p< 0.001). Pregnant women 
absorbed significantly more non-heme Fe than non-pregnant women (p< 0.001), but 
no significant differences in heme Fe absorption were evident between the pregnant 
and non-pregnant women. The relative difference in heme versus non-heme Fe 
absorption was significantly lower in the pregnant women compared to the mean 
difference observed among the non-pregnant women (7.4  14% vs. 35  14%, 
p<0.001). Mean Fe absorption was not significantly affected by the order in which the 
two forms of Fe were fed.  Estimations used for blood volume and RBC incorporation 
may impact the absolute values of absorption obtained. To minimize this possibility 
while assessing differences between groups the ratio of absorbed heme iron to non-
heme iron (
58
Fe absorption/
57
Fe absorption) was compared between the pregnant (1.26 
± 0.44) and non-pregnant (4.8 ± 3.1) subjects and was also found to be significantly 
different (p = 0.003).  
In pregnant subjects non-heme Fe absorption was inversely associated with 
TBI (p = 0.02, r
2
= 0.29) and hemoglobin (p = 0.04 r
2
= 0.24) and directly associated 
with TfR (p = 0.003 r
2
= 0.43). When the two PE patients were excluded the 
relationship between non-heme Fe absorption and hemoglobin lost significance. In 
contrast, relationships between heme Fe absorption and maternal TBI (p = 0.08) and 
TfR (p = 0.06) during pregnancy only approached significance. In non-pregnant 
subjects neither non-heme nor heme Fe absorption were significantly related to Fe 
status indicators with the exception of TfR which was significantly related to heme Fe 
absorption (p = 0.04, r
2
= 0.39). During pregnancy heme iron absorption was inversely 
associated with age (p = 0.02, r
2= 0.29) with pregnant adolescents (≤ 18 y) absorbing 
significantly more heme Fe than adult women (p< 0.001). Absorption of ferrous 
 79 
 
sulfate did not significantly differ between pregnant adolescents and adults. Age was 
not associated with serum hepcidin or measures of iron status and there were no 
significant differences in Fe status, serum hepcidin, parity, race/ethnicity, gestational 
age or BMI between the pregnant adolescents and adults in the study.  Neither heme 
nor non-heme iron absorption were related to BMI, leptin or CRP.  Among the 
pregnant subjects, CRP was directly related to serum hepcidin (p = 0.005), however, 
the relationship was no longer significant if the two subjects with preeclampsia were 
excluded. Likewise, serum hepcidin was not significantly associated with BMI or 
leptin. 
As expected, serum hepcidin was related to iron status. In pregnant women 
hepcidin was directly associated with serum ferritin (p< 0.001, r
2
= 0.61) and TBI (p< 
0.001 r
2
= 0.51). Similar but less significant relationships were noted in the non-
pregnant subjects with serum hepcidin being significantly related to serum ferritin (p = 
0.03 r
2
= 0.43) and TBI (p = 0.03 r
2
= 0.44). 
 Hepcidin was also significantly correlated with  non-heme Fe absorption (p = 
0.04, r
2
= 0.14) when data from the pregnant and non-pregnant subjects were combined 
(n = 29). When the two subjects with PE were excluded from the analysis this 
relationship was further strengthened (p = 0.009, r
2
= 0.24). Pregnant and non-pregnant 
subjects with non-detectable (<5 μg/L) serum hepcidin levels had significantly greater 
non-heme Fe absorption compared to subjects with detectable serum hepcidin (p = 
0.02, n = 29). In contrast, heme Fe absorption was not significantly associated with 
serum hepcidin in the group as a whole or within the non-pregnant or pregnant 
cohorts. Moreover, no significant differences in heme Fe absorption were evident 
between those with detectable versus non-detectable serum hepcidin levels.  
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Discussion  
Both pregnant and non-pregnant women absorbed a significantly higher 
fraction of dietary iron from an animal-based heme source compared to Fe absorption 
from ferrous sulfate. During pregnancy daily absorbed iron requirements increase ~4-
fold presumably to support gestational Fe losses to the fetus, placenta and post-partum 
blood loss (22).  During pregnancy the dietary recommendations for iron increase by 
~9 mg/d (to 27 mg iron/day), which is typically met by supplemental iron. According 
to US data 36% of women are non-compliant with prenatal iron supplementation 
recommendations and use is often lowest in those at highest risk for anemia (low-
income, black women) (23;24). In our study iron absorption was assessed from ~9 mg 
of ferrous sulfate compared to a similar Fe dose from meat. Our data indicated a 
typical animal-based meal containing ~9 mg of iron could provide ~95% of the daily 
absorbed iron requirement during pregnancy versus 81% which would be obtained 
from ~9 mg of ferrous sulfate given alone without a meal to fasted women (assuming 
an absorbed daily iron intake requirement of 4.5 mg). The non-heme dose was given 
under optimal absorption conditions (fasted, low-dose liquid with ascorbic acid) and 
when taken as part of a meal absorption would likely decrease. Prenatal supplements 
typically contain 30 - 60 mg of iron, and in our previous research pregnant women 
absorbed ~ 9.9 % from a 60 mg Fe supplement, which would exceed average iron 
requirements if taken on a regular basis (17). 
The relative difference in absorption between the two Fe sources was 
significantly different between the pregnant and non-pregnant women. Among the 
non-pregnant women there was a 3.3 fold difference in Fe absorption from 
intrinsically-labeled pork versus ferrous sulfate compared to only a 1.2 fold increase 
during pregnancy. Similar differences in upregulation of heme iron absorption were 
evident when results were expressed as the ratio of heme to non-heme Fe absorption. 
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The lower difference in heme versus non-heme iron absorption observed among 
pregnant women was likely a consequence of their reduced iron stores.  Lower iron 
stores were associated with significantly lower serum hepcidin among pregnant 
women. Down-regulation of hepcidin allows for an increased efflux of non-heme iron 
across the enterocyte. Although mechanisms of heme absorption remain 
uncharacterized, iron stores are thought to have less impact on heme iron absorption 
than on non-heme Fe absorption (7). A similar attenuated relationship between iron 
stores and heme Fe absorption was reported among blood donors (lower Fe status) in 
whom a 2-fold difference between heme and non-heme iron absorption was noted 
compared to the 5-fold difference in Fe-replete non-blood donors (7).  The marked 
differences in iron status among our pregnant and non-pregnant subjects preclude us 
from making conclusions on the impact of pregnancy alone on heme and non-heme 
iron absorption. Additional research is needed to further understand the role of 
pregnancy, independent of iron status, on upregulating iron absorption. Not 
surprisingly given the fact that teen pregnancy disproportionately impact minorities. 
Although race was differed between the pregnant and non-pregnant cohort – at present 
there are no race-specific differences for iron deficiency nor is there any data to 
suggest cellular mechanisms of iron transport vary as a function of race. 
The role of hepcidin in the regulation of Fe absorption during pregnancy has 
been largely unexplored. In the current study serum hepcidin was inversely associated 
with markers of Fe status in pregnant and non-pregnant populations. Likewise, 
previous research has found relationships between urinary hepcidin and maternal iron 
status (25). In our study non-heme Fe absorption was inversely related to serum 
hepcidin; women with non-detectable levels of serum hepcidin had significantly 
greater non-heme Fe absorption. Serum hepcidin explained ~24% of the variation in 
non-heme Fe absorption in healthy pregnant and non-pregnant subjects, which is 
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similar to our previous research in non-pregnant women (26%) (9).  Likewise animal 
data have found hepatic hepcidin expression to decrease during pregnancy resulting in 
increased Fe absorption  (26). Hepcidin regulates non-heme Fe absorption by binding 
to ferroportin, the sole known non-heme Fe exporter in the enterocyte, effectively 
blocking Fe flux (27). Hepcidin may also inhibit apical iron uptake in the enterocyte 
(28).  The process by which heme exits the enterocyte has not been definitively 
characterized; it is not known if all of heme is degraded within the cell such that it is 
exported entirely using non-heme iron transport mechanisms or if some heme iron 
exits intact (29). These differences in iron metabolism may explain the lack of 
association between heme Fe absorption and hepcidin.  
Limitations of the current study design include our estimation of RBC Fe 
incorporation. Assessment of this value in each subject would have required an 
infusion of a third stable Fe isotope and would have impacted our ability to adjust data 
obtained for isotopic fractionation. We chose instead to focus on the comparison in 
relative differences in bioavailability of the two oral forms of Fe ingested. With this 
approach each woman was their own control and differences in RBC Fe incorporation 
would not impact the relative absorption value.  Because an intravenous tracer was not 
administered we estimated the fraction of absorbed Fe that would be incorporated into 
RBCs. In non-pregnant subjects this is relatively stable and typically averages 80% 
and we chose to use the same value for pregnant subjects. However, estimates of RBC 
Fe incorporation during pregnancy can be highly variable and we have previously 
found this to be affected by Fe supplementation and maternal serum ferritin (17).  
Other researchers have found values of RBC Fe incorporation as low as 70% (20) or 
65% (30) during pregnancy. We re-fit our data using the reported estimate of 65% in 
place of 80% and found that this would increase non-heme Fe absorption from 40.4% 
to 49.8% and heme Fe absorption from 47.7% to 58.7% but did not change any of the 
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significant relationships reported.  Furthermore, incorporation of dietary iron into 
maternal RBCs during pregnancy reflects maternal utilization of iron but does not 
capture the amount of iron that was transferred directly to the fetus. Early radiotracer 
studies demonstrated that placental transfer of orally ingested iron occurs within 
minutes of injection (31) or within hours of ingestion (32). In a prior study of non-
heme iron absorption we found that the amount of non-heme dietary Fe transferred to 
the fetus underestimated maternal Fe absorption by approximately 5% (33).   
 In summary, heme iron absorption was not influenced by maternal iron stores 
or serum hepcidin in either the pregnant or non-pregnant women. Absorption of heme 
iron was significantly greater than absorption of a similar load of non-heme, 
supplemental iron.  Compliance with prenatal iron supplementation is often lowest in 
those with the greatest risk of anemia thus emphasis on how to best meet iron 
requirements from the diet alone is an important concern. The significantly greater 
bioavailability of heme iron may help achieve dietary iron demands during pregnancy.   
Further research is required to understand the mechanisms by which heme iron 
absorption is enhanced and to characterize the ability of these two forms of iron to 
provide for fetal iron demand. 
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Abstract 
Background: Determinants of placental transport of dietary iron (Fe) remain largely 
uncharacterized.  
Objective:  To elucidate the determinants of heme and non-heme Fe transfer to the 
neonate. 
Design:  A sample of 19 pregnant females (age 16-32 y) ingested intrinsically labeled 
58
Fe-heme and a non-heme iron source (
57
Fe as ferrous sulfate) during the third 
trimester of pregnancy.  At delivery maternal and cord blood samples were obtained to 
assess Fe transfer to the neonate as a function of maternal/neonatal Fe status (serum 
ferritin (SF), transferrin receptor (TfR), hemoglobin (Hb), total body iron (TBI) and 
serum hepcidin). 
Results: There was a significantly greater enrichment of 
58
Fe-heme tracer in cord 
blood compared to 
57
Fe-non-heme tracer enrichment (p = 0.02) and a greater fraction 
of the maternally absorbed heme Fe was transferred to the neonate (p < 0.0001). Net 
non-heme Fe (mg) transferred to the neonate was related to maternal SF (p = 0.0008), 
Hb (p = 0.005), TBI (p < 0.0001), TfR (p = 0.0002) and serum hepcidin (p = 0.002) at 
delivery. Likewise, net heme Fe (mg) transferred was associated with maternal SF (p 
= 0.003), Hb (p = 0.02), TBI (p = 0.001), TfR (p = 0.01) and serum hepcidin (p = 
0.004). Iron transfer of both heme and non-heme iron was also associated with 
neonatal Hb (p = 0.008, p = 0.004). Mothers with non-detectable serum hepcidin 
transferred significantly more non-heme (p = 0.003) and heme (p = 0.002) Fe to their 
neonates than subjects with detectable levels.  
Conclusion: There appears to be preferential fetal utilization of maternally ingested 
heme Fe compared to non-heme Fe during pregnancy. Maternal serum hepcidin and 
maternal/neonatal Fe status play a role in regulating heme and non-heme iron transfer. 
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Introduction 
Neonatal iron (Fe) endowment at birth has increasingly been recognized as an 
important factor in subsequent health outcomes (1). During the third trimester of 
pregnancy the fetus obtains the majority of its Fe stores and suboptimal placental Fe 
transfer may set the stage for increased risk of postnatal Fe insufficiency.  The 
importance of maternal Fe status in the establishment of the neonatal Fe endowment at 
birth has been controversial. Previously, the fetus was believed to be a “perfect parasite” 
capable of extracting all necessary Fe from the mother regardless of her Fe stores. 
However, there are now growing data to support a relationship between maternal anemia 
and suboptimal neonatal Fe status at birth (2-5). Moreover, there is a growing 
recognition of the long-term and irreversible effects of neonatal anemia on cognitive, 
motor and social-emotional outcomes (6-8). We previously reported a relationship 
between maternal Fe status and transfer of non-heme Fe to the fetus (9;10). However, 
the regulation of heme Fe metabolism during pregnancy remains largely unexplored. 
Hepcidin is a systemic regulator of Fe homeostasis and functions by binding to 
ferroportin and causing it to be internalized, thereby blocking Fe export from the 
enterocyte and Fe release from macrophages and the liver (11). At this time there are 
limited human data on the role of hepcidin in the regulation of placental heme or non-
heme Fe transport, although animal data has suggested a link between hepcidin and 
non-heme Fe homeostasis during pregnancy (12;13). The goal of this study was to 
evaluate placental Fe transfer of both dietary heme and non-heme Fe during the third 
trimester of pregnancy in relation to maternal and neonatal Fe status and serum 
hepcidin. 
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Subjects and Methods  
Twenty pregnant study volunteers, age 16-32 years, were recruited from the 
Strong Midwifery Group and the Rochester Adolescent Maternity Program (RAMP) 
in Rochester, NY. Only healthy non-smoking females with uncomplicated pregnancies 
were asked to participate. Women and adolescents were excluded if they had 
gestational diabetes, hypertension, preeclampsia, underlying malabsorption diseases or 
medical problems known to impact Fe homeostasis at the time of enrollment. The 
study was approved by the Institutional Review Board of Cornell University and the 
University of Rochester Research Subjects Review Board and informed written 
consent was obtained from all subjects. The study was registered with 
clinicaltrials.gov as NCT01019096 (http://www.clinicaltrials.gov). Data on Fe 
absorption in these study participants was discussed in Chapter 3. 
 
Isotope Preparation 
 Iron isotopes were purchased from Trace Sciences International (Ontario, 
Canada) as the metal (
57
Fe at 94.69% enrichment and 
58
Fe at 93.34% enrichment). The 
non-heme Fe tracer (
57
Fe) was converted into ferrous sulfate solution by Anazao Health 
(Tampa, FL). The Fe tracer used to intrinsically label heme (
58
Fe) was converted into 
ferrous citrate and then analyzed for sterility by Analytical Research Labs (Oklahoma 
City, OK). Iron isotopic composition of the final tracer solutions tracers were assessed 
using a Thermo Scientific Triton TI Magnetic Sector Thermal Ionization Mass 
Spectrometer (TIMS) (Thermo Fisher Scientific Inc, Bremen, Germany). Intrinsic heme 
labeling was undertaken at Baylor College of Medicine using a protocol approved by 
their Animal Use Committee. Methods were adapted from a previous study by 
Etcheverry et al. (14). Briefly, intrinsic labeling of the porcine muscle and red blood 
cells (RBC) Fe was accomplished by two intramuscular 75 mg doses of 
58
Fe into a 3-
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day old female piglet. The piglet was sacrificed after 28 days at a USDA and State of 
Texas approved facility at Texas A&M University. Red blood cells, a rich source of Hb, 
and muscle, a rich source of myoglobin, were collected and used as the labeled heme Fe 
source for the study. The muscle (
58
Fe enrichment of 18.0 ± 0.80%) and red blood cells 
(
58
Fe enrichment of 17.3 ± 0.01%) were analyzed separately for enrichment of 
58
Fe by 
TIMS as previously reported in Chapter 3. 
 
Study design and isotope dosing 
Subjects participated in a 2-day Fe absorption study during the third trimester 
of pregnancy (week 32-35 of gestation) at Strong Memorial Hospital’s Clinical and 
Translational Science Center (CTSC). All subjects discontinued any Fe or prenatal 
supplementation for three days prior to the first day of Fe dosing. Fasted participants 
were asked to come to the CTSC on two consecutive days. Each individual’s height 
and weight were taken with the use of a stadiometer and a calibrated scale on the 
morning of the first study day. On each test day a standard breakfast was provided and 
each research participant then remained in the CTSC for two hours before receiving 
each Fe test meal.  All participants consumed both a heme (
58
Fe intrinsically labeled 
ground pork) and non-heme (
57
Fe as ferrous sulfate) test meal in a random order. The 
heme Fe dose included approximately 203 grams of enriched ground pork and 3.9 
grams of enriched RBCs cooked into a chili mix with tomato sauce (Hunts, Dallas, 
TX) and chili seasoning (McCormick, Sparks, MD). The net Fe load ingested from the 
heme and non-heme test meals were similar with each containing approximately 8 mg 
of iron. The heme meal provided 0.46 mg of labeled 
58
Fe from intrinsically labeled 
pork muscle and 0.46 mg from intrinsically labeled RBCs for a total dose of 0.92 mg 
58
Fe (total Fe, 7.9 mg). The non-heme Fe dose consisted of an oral dose of 8.2 mg of 
57
Fe as ferrous sulfate (total Fe, 8.6 mg) flavored with 2 mL of raspberry syrup 
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containing ascorbic acid (Humco, Texarkana, TX) without food. The total Fe content 
of the heme meal and non-heme Fe dose was validated using atomic absorption 
spectrophotometry (AAS) (PerkinElmer Analyst 800; PerkinElmer Inc, Norwalk, CT). 
Pregnant women and adolescents  remained in the CTSC for two hours after ingesting 
each test meal before being fed a standard lunch. Standard dinner and snacks were 
provided for the subjects to take home and consume. Pregnant adolescents remained as 
inpatients overnight at the CTSC to avoid transportation difficulties and to insure food 
intake was controlled. On the second test day, the same foods in the same amounts 
were consumed as those ingested on the first day.  
All study participants were followed until delivery and their medical charts 
were flagged to insure delivery samples would be obtained.  At admission a 15 mL 
maternal blood sample was obtained and at delivery a 30 mL cord blood sample was 
taken.  
 
Laboratory Analysis 
Whole blood samples collected at delivery were transported to Strong 
Memorial Hospital’s clinical laboratory for analysis of hemoglobin (Hb) using the Cell 
Dyn 4000 system. Hemoglobin measures were also obtained at bedside using a 
HemoCue (Lake Forest, CA).  When clinical laboratory values for neonatal 
hemoglobin were not available (due to logistical and technical problems with sample 
clotting, etc.) the HemoCue values were utilized. In other whole blood samples, serum 
was separated on site and shipped to Cornell on dry ice for analysis of Fe status 
indicators. Serum ferritin (SF) and serum soluble transferrin receptor (TfR) were 
measured with commercially available kits from Ramco Laboratories, Inc. (Stafford 
Texas).  
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From these two markers, total body Fe was calculated as described by Cook et al.; 
(total body iron, TBI, (mg/kg) = -[log (serum transferrin receptor/serum ferritin) – 
2.8229]/0.1207) (15).  C-reactive protein (CRP), serum folate, vitamin B12 and 
erythropoietin (EPO) were measured using the Immulite
®
1000 immunoassay system 
(Tarrytown, NY). Intrinsic Life Sciences measured maternal and neonatal serum 
hepcidin using a competitive serum enzyme-linked immunosorbent assay (C-ELISA) 
specific for the mature peptide (Intrinsic Life Sciences, La Jolla California) (16). The 
lower limit of detection for this assay is 5 µg/L (16).  
  
Isolation of iron from samples/mass spectrometry 
 Samples of whole blood (0.5 mL) were digested with 2 mL of nitric acid and 
0.1 mL hydrogen peroxide by heating in glass flasks on a hot plate. Digested samples 
were evaporated to dryness and reconstituted in 2 mL of ultrapure 6M hydrochloric 
acid (Ultrex, JT Baker). Iron was extracted from the digested blood samples using 
anion exchange chromatography. The eluate was dried on a hot plate and then 
reconstituted in 40 μL 3% nitric acid. Extracted Fe samples (8 μL), silica gel (3 μL) 
(Sigma-Aldrich, Inc., St. Louis, MO) and 0.7 N phosphoric acid (3 μL) were loaded 
onto degassed ultrapure zone-refined rhenium filaments (H. Cross Company 
Weehawken, NY). Iron isotope ratios (
57/56
Fe , 
58/56
Fe and 
54/56
Fe ) were measured 
using TIMS (9).  All acids used were ultrapure (Ultrex JT BAKER, Phillpsburg, NJ). 
 
Calculation of iron transfer to neonate 
As denoted in Figure 4.1, the oral iron tracer administered to the pregnant 
women has two primary fates once it crosses the enterocyte, it is either incorporated 
into the maternal RBC or used for maternal stores or it is transported across the 
placenta to be incorporated into the neonate’s RBC or used for neonatal iron stores.  
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Figure 4.1 Iron Partitioning During Pregnancy 
 Partitioning of the two oral iron stable isotopes (
57
Fe and 
58
Fe) administered to 
pregnant women in the third trimester of pregnancy was assessed by three primary 
methods. The first method assessed the dose adjusted delta percent enrichment of each 
isotope in the neonatal RBC. The second method calculated the net milligrams of 
tracer present in the neonatal RBC mass divided by the net tracer ingested by the 
mother. The final approach assessed the net amount of iron isotope present in maternal 
and neonatal RBC then looked at the relative partitioning of absorbed isotope between 
the mother and the neonate as a fraction of the total isotope recovered in RBC’s.   
Oral Fe Dose Administered:
Heme, 58Fe
Non-Heme, 57Fe
58Fe
57Fe
Maternal
Enterocyte
Maternal RBC
Neonatal Utilization
Maternal Utilization
Maternal
Fetal
Neonatal RBC
Placenta
#1 57Fe/58Fe
#2 Mg Tracer in Neonate 
Tracer Dose Ingested
#3  Absorbed Tracer
(Total mass of absorbed tracer  in  maternal and neonatal RBC)
% Absorbed Tracer
in Maternal RBC
% Absorbed Tracer in 
Neonatal RBC
96 
As discussed in Chapter 3, measures of iron absorption during pregnancy 
should more accurately be described as maternal utilization. Isotope enrichment in 
maternal RBC underestimates net maternal absorption because a fraction of the 
absorbed iron is directly transferred to the neonate. Previous research has indicated 
that approximately 7.5% of the absorbed non-heme iron tracer is found in the neonate 
at birth when compared to the circulating mass of iron present in the maternal RBC 
(10). Iron transfer to the fetus is also known to be rapid and is not significantly related 
to the time between dosing and delivery, indicating that there is negligible transfer of 
the tracer once incorporated in the mother’s RBC (10;17;18). Thus isotopic 
enrichment in the maternal and cord blood samples gives a good depiction of maternal 
iron partitioning during late pregnancy.  
In our study placental iron transfer was assessed in multiple ways as described 
below. Each step attempts to more accurately characterize the net amount of iron 
transferred to the neonate but each step is also dependent on additional assumptions of 
neonatal/maternal blood volume and fraction of iron incorporated into the 
neonatal/maternal RBC and therefore may be introducing more error into the 
estimates. It is important to note that while this may impact the estimate of the 
absolute quantity of iron incorporated it should not impact relative differences 
observed between heme and non-heme iron transfer within a subject as the 
assumptions utilized are identical for both tracers.  
 
Approach 1 
For the first approach utilized; enrichment of 
57
Fe and 
58
Fe in cord blood was 
directly analyzed. The delta percent enrichment of each isotope was measured as the 
degree to which the natural abundance ratio was increased as a result of red blood cell 
incorporation of the stable Fe tracer as previously reported (10) using the formula:  
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#1) Δ % enrichment 57Fe = 
 (
57/56
Fe ratio in sample - 
57/56
Fe natural abundance ratio)* 100   
     
57/56
Fe natural abundance ratio  
 
The same equation was utilized for the delta percent enrichment of 
58
Fe from 
the labeled heme meal. The natural abundance Fe isotopic ratios utilized were 0.02317 
for 
57/56
Fe and 0.00307 for 
58/56
Fe.  
Doses of each isotope were selected to achieve the same relative enrichment in 
blood assuming that each tracer dose was absorbed to the same extent (i.e. a dose of 
10 mg 
57
Fe would give the same enrichment as a dose of 1.34 mg of 
58
Fe given the 
differences in the natural abundance of each tracer (natural abundance (NA) values 
utilized were 0.0214 for NA57 and 0.00287 for NA58).  Subtle differences in net dose 
administered occurred between subjects. To control for this variability, all measures 
used a dose adjusted delta % enrichment for both the 
57
Fe and 
58
Fe. For this measure 
the observed delta percent excess in cord blood and actual dose administered was used 
to obtain an expected delta percent excess using the mean tracer dose of 
57
Fe 
administered (8.2 mg) and a corresponding mean dose of 
58
Fe of 1.1 mg. 
 
Approach 2 
To further characterize partitioning of iron to the fetus the amount of iron in 
the neonate was examined as a fraction of iron tracer dose given to the mother (Figure 
4.1). To obtain this measure the neonatal mass of circulating iron was first estimated 
assuming a neonatal blood volume of 80 mL per kilogram (19;20) and an Fe content 
of hemoglobin of 3.47 g/kg (21;22) with the following formula: 
Total circulating neonatal iron (Fecirc) =  
Blood volume (80 mL/kg) * Hb (kg/L) * Wt (kg) * [Fe] of Hb (3.47 g/kg) 
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The net mg quantity of Fe isotope present in the infant circulation was then calculated 
for both the heme and non-heme Fe as; 
 
Net non-heme iron transfer (mg) = 
    (EQN 1)
 
  (Dose adjusted Δ % enrichment 57Fe/100)* (Fecirc )* (NA57)   
 
The same equation was utilized for the 
58
Fe tracer substituting in NA58 and the dose 
adjusted delta % enrichment of 
58
Fe to calculate the net heme Fe transfer. Additional 
calculations were undertaken to account for the small amount of 
58
Fe that was present 
and absorbed from the 
57
Fe tracer, as the 
57
Fe tracer contained 2.1% of 
58
Fe.  
 
#2) Percent of Maternal Ingested Non-heme Fe Tracer Transferred to Neonate =   
(Net non-heme Fe transfer- EQN 1 / Mean maternal 
57
Fe dose (mg) administered)*100 
 
A similar equation was used to calculate the net heme Fe transfer as a fraction of the 
corrected mean dose of 
58
Fe administered to the mother (percent of maternal ingested 
heme Fe tracer transferred to neonate). This approach uses estimates of neonatal blood 
volume and circulating neonatal iron mass.  
 
 
Approach 3 
Finally the relative partitioning of net absorbed iron tracer was examined in 
relation to the total quantity of dose recovered in the maternal and neonatal RBCs. The 
total mg recovered in the mother was calculated with the following formula; % Non-
heme Fe absorption *0.01 * 
57
Fe dose/ RBC incorporation. Equation 1 above details 
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the net mg recovered in the neonate. The total absorbed dose was calculated as the 
sum of these two net quantities.  
 
Total Absorbed Tracer Dose =  
mg recovered in neonate (EQN-1) + mg recovered in mother  
 
Then the relative partitioning of tracer to the neonate could be calculated by the 
following formula: 
 
#3) % of Maternal Absorbed Non-Heme Fe Tracer Transferred to Neonate = 
(Net non-heme Fe transfer- EQN 1)  * (100) _ 
Total Absorbed Dose 
A similar equation was utilized for heme Fe to calculate the percent of 
maternal heme dose absorbed and transferred to the neonate (percent of maternal 
absorbed heme Fe tracer transferred to neonate). This equation has the advantage of 
taking into account differences in iron absorption and examining relative partitioning 
of the isotope; however, estimates on maternal RBC incorporation and neonatal/ 
maternal blood volume and circulating iron mass are utilized in the calculations.  
 
Data analysis 
All statistical analyses were completed using JMP 8.0 (SAS Institute INC, 
Cary, NC). Variables that were not normally distributed were transformed prior to 
statistical testing (using the natural log). Linear regression analyses were used to 
examine the relationships between Fe status, hepcidin and placental transfer. Multiple 
linear regression analyses using forward stepwise regression were utilized to identify 
significant determinants of heme and non-heme placental Fe transfer. The significance 
of relationships between heme and non-heme Fe transfer and Fe status within subject 
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groups was assessed using Paired t-tests. Non-detectable serum hepcidin levels (< 5 
ng/mL) were given a value of 2.5 ng/mL for data analysis purposes, as reported in 
Chapter 3. Results were analyzed with and without the two subjects that developed 
preeclampsia (PE). Unless specifically stated otherwise the results and p-vales are 
given for the complete sample size (including PE subjects). If inclusion of the PE 
subjects impacted significance of results obtained, this was highlighted. Our sample 
size of 20 subjects was selected to detect a 1.1% difference in delta percent enrichment 
of 
57
Fe vs. 
58
Fe in cord blood with a power of 80% and an alpha level of 0.05 and an 
estimated attrition rate of 20% using the mean and standard deviation in a prior study 
of placental non-heme transfer (10).  Differences were considered significant if p < 
0.05. 
 
Results 
General characteristics of the study subjects are shown in Table 4.1. Of the 
original 20 subjects, one pregnant adolescent was withdrawn from the study because 
she did not finish the pork meal; therefore only 19 study participants were followed to 
delivery. Of these 19 participants, one adult did not show up for the two-week blood 
draw so Fe absorption data was not available for that subject but maternal and cord 
blood samples were collected at delivery.  
 In total 84% (16/19) of the participants had term deliveries (≥ 37 weeks 
gestation) and 21% (4/19) gave birth to a LBW infant (< 2500 g; mean birth weight of 
2408 ± 74 g).  Among the 3 preterm births; one adult subject had a spontaneous 
preterm birth and the other two were induced because they developed PE (one 
adult/one adolescent). All preterm births resulted in LBW infants. One additional adult 
with a term pregnancy also gave birth to a LBW infant. There were no differences in 
primary outcomes between the adult and teen subjects.  
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1
All values are mean ± SD (range in parentheses) 
2
All values are median ± SD (range in parentheses) 
 
 
 
Table 4.1  
General characteristics of mothers and neonates at delivery
1,2
 
  
Variable  Pregnant (n = 19) 
  
Gestational Age at Delivery (wks) 39.9   1.6 (36.0 - 41.6) 2 
  
Maternal Age (yrs) 19.0  2.9 (16.0 - 32) 2 
  
Parity 0  0.9 (0-3) 2 
  
Pre-pregnancy BMI (kg/m
2
) 24.7  7.0 (20.7 - 43.6) 2 
  
Delivery BMI (kg/m
2
) 30.4   7.1 (24.4 – 47.5) 2 
  
Gestational Weight Gain (lbs) 39.7  15.0 (19-76)1 
  
Infant weight (grams) 3169.7  548 (2298-3949) 1 
  
Race  
      African American 53% 
      Caucasian 47% 
  
Ethnicity  
      Hispanic 37% 
      Non-Hispanic  63% 
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Iron status indicators in mothers and their neonates at delivery are described in 
Table 4.2. No significant differences in the hemoglobin values were evident between 
the Hemocue vs. the core laboratory value. At delivery 42% of the subjects had 
depleted  iron stores (Hb < 11 g/dL, serum ferritin < 20 μg/L). Approximately 45% of 
the subjects had non-detectable levels of serum hepcidin at delivery (< 5 ng/mL), 
whereas all of the neonates had detectable serum hepcidin at birth.         
Hepcidin and Iron Status  
Maternal serum hepcidin concentrations were significantly associated with 
multiple indicators of Fe status in the mother at delivery [SF (p = 0.0001, r
2
 = 0.59), 
TBI (p = 0.0001, r
2
 = 0.59), Hb (p = 0.01, r
2
 = 0.31) and TfR (p = 0.01, r
2
 = 0.31)]. 
Similarly neonatal serum hepcidin was directly associated with both neonatal serum 
ferritin (<0.0001, r
2
 = 0.60) and neonatal total body Fe (p = 0.0001, r
2
 = 0.60). While 
relationships were evident within the individual neonate or mother at delivery, 
maternal serum hepcidin was not significantly related to neonatal serum hepcidin or 
other markers of Fe status in the neonate. Measures of leptin and BMI were not 
significantly associated with serum hepcidin, placental iron transfer, or iron status in 
the mother or neonate.  
Heme and Non-Heme Iron Transfer to Neonate  
There was a significantly greater dose adjusted delta percent enrichment of the 
58
Fe-heme tracer in cord blood compared to the 
57
Fe-non-heme tracer enrichment (p = 
0.02) Table 4.3.  The differences in Fe transfer between the two isotopes remained 
significant if presented as percent maternal ingested iron tracer transferred or percent 
of maternal absorbed tracer transferred to neonate. Similar to our previous data on 
transfer of non-heme Fe to the fetus (10), no significant relationship was evident 
between neonatal enrichment of either the heme or the non-heme Fe tracers and the 
number of days that had elapsed between dosing and delivery.       
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Table 4.2 
Iron status indicators for mother and neonate at delivery 
   
Variable 
Maternal  
 (n = 19) 
Neonate  
(n = 19) 
Hemoglobin (g/dL) 
       < 11 g/dL ( % Anemic)  
 
11.1  1.2 1, a 
42% 
 
13.4  3.0 1, b 
 
 
   
Serum ferritin (μg/L) 
    < 12 μg/L (% Fe Deficiency) 
    < 20 μg/L (% Fe Depletion) 
25.4  20.6 2, a 
16% 
42% 
134.9  110.2 2,b 
 
 
   
Serum transferrin receptor (mg/L) 
    > 8.5 mg/L  
5.5  3.3 2, a 
21% 
8.35  2.1 1, a 
 
   
Total Body Iron (mg/kg) 
    < 0 mg/kg  
3.4  3.9 1, a 
16% 
8.6  2.7 1, b 
 
   
Serum hepcidin (μg/L) 9.3  58.1 2, a 61.7  77.0 2,b 
   
C-reactive protein (mg/L)
 
 6.1  14.7 2,a 0.2  0.15 2,b 
   
Folate (nmol/L) 38.0  18.5 2,a 69.4  26.6 1,b 
   
Vitamin B-12 (pmol/L) 262.2  123 1,a 539.5  547 2,b 
   
Erythropoietin  (IU/L) 24.8  23 2,a 29.7  74 2,a 
   
Leptin (μg/L) 41.0  22.2 1,a 7.3  9.6 2,b 
1
All values are mean ± SD  
2
All values are median ± SD  
Means that are significantly different from each other are denoted with  a 
different letter (p <0.05) 
 104 
 
  
Relationships between net neonatal non-heme Fe transfer and maternal Fe 
status were explored. A significant inverse association was found between net non-
heme Fe transfer (mg) with maternal serum ferritin (p = 0.0008, r
2
 = 0.49), 
hemoglobin (p = 0.005, r
2
 = 0.38) and total body Fe (p<0.0001, r
2
 = 0.64) (Figure 
4.2).  Net non-heme Fe transfer (mg) was directly associated with maternal transferrin 
receptor (p = 0.0002, r
2
 = 0.58) and with maternal percent absorption of non-heme (p 
= 0.002, r
2
 = 0.47).   
 
Table 4.3 
Placental Fe Transfer to the Neonate
1
 
    
Variable 
Non-heme 
(
57
Fe) 
Heme (
58
Fe) P-value 
Δ % enrichment in cord 
(dose adjusted)
2
 
6.9  3.2 8.4  3.2 0.02 
    
% of Maternal Ingested Fe Tracer 
Transferred to Neonate
3
 
2.2  1.4 2.7  1.3 0.02 
    
% of Maternal Absorbed Fe Tracer 
Transferred to Neonate
4
 
4.0  1.6 
 
5.4  2.4 
 
<0.0001 
    
1
All values are mean ± SD,  P-values are provided for paired t-tests  
2
 Percent excess was adjusted for the natural abundance of isotope 
administered and for small differences in dose received. 
3
 Quantity of tracer dose in neonate divided by average tracer dose 
administered to mother. 
4 
Quantity of tracer dose in neonate as fraction of the absorbed tracer dose. 
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Figure 4.2 Net Iron Transfer and Maternal Total Body Iron 
 Heme (intrinsically labeled 
58
Fe pork) and non-heme (
57
Fe as ferrous sulfate) iron 
were given to 19 pregnant subjects during the third trimester of pregnancy. The net 
quantity of each tracer in neonatal hemoglobin at birth was assessed from enrichment 
of cord blood samples.  Maternal total body iron (mg/kg) at delivery was inversely 
associated with both net neonatal non-heme (p <0.0001, r
2
 = 0.64) and heme (p = 
0.001, r
2
 = 0.47) iron transfer (mg). 
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Interestingly net neonatal non-heme Fe transfer (mg) was also inversely 
associated with maternal serum hepcidin at delivery (p = 0.002, r
2
 = 0.43). Pregnant 
subjects with non-detectable levels of serum hepcidin transferred a significantly 
greater net quantity of the non-heme tracer (mg) to their neonates than subjects with 
detectable levels of serum hepcidin (p = 0.003). As illustrated in Figure 4.3 the 
percent of maternal ingested non-heme Fe tracer transferred to neonate was 
significantly greater in subjects with non-detectable serum hepcidin (p = 0.003). 
Differences remained significant if percent of maternal absorbed non-heme tracer 
transferred to neonate was used in place of net mg transferred (p = 0.03). Likewise 
mothers with depleted Fe stores (serum ferritin < 20 μg/L) transferred significantly 
more non-heme Fe (mg) to the neonate than Fe replete subjects (p = 0.02).  Net 
neonatal non-heme Fe transfer was positively associated with maternal EPO (p = 0.01, 
r
2
 = 0.32). Non-heme Fe transfer was associated with maternal CRP (p = 0.03, r
2
 = 
0.25), however if the two subjects with PE (CRP: 66 mg/L, 6 mg/L) were excluded the 
relationship lost significance (p = 0.06). Examination of relationships between net 
non-heme Fe transfer to the neonate and neonatal Fe status showed that net non-heme 
Fe transfer was directly associated with neonatal hemoglobin (p = 0.004, r
2
 = 0.39) 
and weakly associated with neonatal serum ferritin (p = 0.09, r
2
 = 0.16), neonatal total 
body Fe (p = 0.1, r
2
 = 0.13) and neonatal serum hepcidin (p = 0.1, r
2
 = 0.13).  Net non-
heme Fe transfer was significantly associated with EPO in the neonate (p = 0.01, r
2
 = 
0.32). Using a multiple regression model, 92% of the variance in net of non-heme Fe 
(mg) transferred could be explained by a model including cord Hb, infant weight and 
maternal TBI at delivery (p < 0.0001, r
2
 = 0.92). Adding maternal percent non-heme 
Fe absorption to the model did not explain any additional amount of variation in non-
heme Fe transfer and this measure was a non-significant factor in the model after 
controlling for Fe status.  
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Figure 4.3 Heme and Non-Heme Iron Transfer and Serum Hepcidin 
Heme (intrinsically labeled 
58
Fe pork) and non-heme (
57
Fe as ferrous sulfate) iron 
were given to 19 pregnant subjects during the third trimester of pregnancy. The 
fraction of the total amount of each maternally ingested isotope tracer administered to 
the mother and transferred across the placenta to the neonate was assessed in 19 
neonates. Mothers with non-detectable (< 5 µg/L) serum hepcidin at delivery 
transferred a significantly greater quantity of both the heme and non-heme tracers to 
their fetus. Means that are significantly different from each other are denoted with a 
different letter (p <0.05). 
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Like net non-heme Fe transfer, the net mg of heme Fe transferred was also 
significantly associated with both maternal and neonatal Fe status.  Net mg of heme Fe 
transferred was inversely associated with the maternal serum ferritin (p = 0.003, r
2
 = 
0.41), Hb (p = 0.02, r
2
 = 0.30) and total body Fe (p = 0.001, r
2
 = 0.47) (Figure 4.2) 
Net neonatal heme Fe transfer (mg) was directly associated with maternal percent 
absorption of heme Fe (p = 0.01, r
2
 = 0.35) and with TfR (p = 0.01, r
2
 = 0.33) in the 
mother at delivery. Maternal serum hepcidin at delivery was also inversely associated 
with net heme Fe transfer (mg) (p = 0.004, r
2
 = 0.39). As with non-heme Fe transfer, 
mothers with non-detectable serum hepcidin at delivery (p = 0.002) and subjects with 
depleted Fe stores (p = 0.003) transferred a significantly greater net quantity of heme 
Fe to the neonate. Likewise as illustrated in Figure 4.3 the percent of maternal 
ingested heme Fe tracer transferred to neonate was significantly greater in subjects 
with non-detectable serum hepcidin (p = 0.002).  These differences also remained 
significant if percent of maternal absorbed heme Fe tracer transferred to neonate was 
used in place of net mg transferred (p = 0.008). Net heme Fe transfer (mg) was weakly 
associated with EPO in the mother (p = 0.1, r
2
 = 0.15) at delivery. Maternal CRP at 
delivery was inversely associated with net heme Fe transfer (p = 0.02, r
2
 = 0.28), 
however when the two PE subjects were excluded the relationship lost significance (p 
= 0.052, r
2
 = 0.23). 
Net neonatal heme Fe transfer was directly associated with neonatal 
hemoglobin (p = 0.008, r
2
 = 0.35) and was significantly associated with EPO in the 
neonate (p = 0.03, r
2
 = 0.2) but was not significantly related to other measures of Fe 
status. Using a multiple regression model, 79% of the variation in net heme Fe transfer 
(mg) could be explained by cord hemoglobin, infant weight and maternal TBI at 
delivery (p<0.0001, r
2
 = 0.79). If maternal percent heme Fe absorption was added to 
the model an additional 10% of the variation could be explained (p<0.0001, r
2
 = 0.89). 
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Discussion   
A significantly greater fraction of maternally ingested or maternally absorbed 
dietary heme Fe was found in the neonate at birth when compared to that observed for 
non-heme Fe. These data suggest that there may be differential partitioning of heme 
Fe once absorbed. Similarities and differences in the determinants of placental transfer 
of each form of Fe were noted. 
 Fe status in the maternal-neonatal dyad was inversely associated with the net 
transfer of non-heme Fe to the neonate at birth. The percent of maternal absorbed non-
heme Fe tracer transferred to the neonate (4.1%) was slightly lower than we 
previously reported for non-heme transfer to the neonate in Fe supplemented (7.0%) 
and un-supplemented (8.6%) Peruvian women (10).  Likewise in an early radioisotope 
study by Hahn et al., neonates received approximately 7-10% of the Fe absorbed by 
the mother (17). In our current study, 64% of the variation in non-heme Fe transfer to 
the neonate measured during the end of the third trimester of pregnancy could be 
explained solely by maternal total body Fe at delivery. Hepcidin has been 
demonstrated to impact placental non-heme Fe transport using animal models (13;23). 
Interestingly, maternal serum hepcidin was associated with placental transfer of non-
heme Fe but this hormone only explained 43% of the variation in placental non-heme 
Fe transfer and the predictive ability of this hormone was no greater than that found 
using traditional Fe status markers. Moreover, the amount of placental Fe transport 
explained by hepcidin is similar, but slightly higher than the ~25% reported between 
hepcidin and intestinal absorption of non-heme Fe (24). Using stepwise regression 
92% of the variability in net placental transfer of non-heme Fe was explained by a 
model that incorporated maternal total body Fe, neonatal hemoglobin, and infant 
weight. Maternal non-heme Fe absorption was not a significant determinant of 
neonatal enrichment when maternal iron status was included in the model. 
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By using both labeled heme and non-heme Fe, similarities and differences in 
determinants of Fe transfer to the neonate could be explored. Both maternal and 
neonatal Fe status was significantly associated with the net transfer of heme Fe to the 
neonate. Similar to non-heme Fe transfer, maternal total body Fe at delivery explained 
the most variability in neonatal heme Fe transfer but explained less variability for 
heme Fe transport than for non-heme Fe (47% vs. 64%). As for non-heme Fe, 
maternal serum hepcidin was also significantly associated with placental transfer of 
heme Fe but only explained 39% of the variability. A model that incorporated 
maternal TBI, neonatal Hb, and infant weight explained 79% of the variance in heme 
Fe transfer. In contrast to relationships observed for non-heme Fe transfer, when heme 
Fe absorption was added to the model above 89% of the variability was explained. 
Maternal and/or neonatal Fe status appears to have less of an impact on placental 
transport of heme Fe than it does for non-heme Fe. This finding mirrors relationships 
reported in the enterocyte where absorption of heme Fe is also less impacted by Fe 
stores when compared to non-heme Fe (25). 
A greater fraction of the heme Fe dose in the neonate may just indicate greater 
heme iron intestinal uptake in the mother. However this did not explain the differences 
noted, as the dose adjusted percent excess, the net mg transferred as a fraction of the 
maternal ingested tracer and the net mg transferred as a fraction of the amount of Fe 
absorbed by the mother all supported a preferential placental transfer of heme Fe. 
Likewise, our study conclusions were comparable if percent enrichment data (directly 
measured, no assumptions of blood volume or RBC Fe incorporation) were utilized in 
place of absolute mg or percent of dose values. Absolute values for mg of Fe 
transferred to the neonate may be impacted by estimations in our calculations. For 
example, neonatal blood volume was estimated in our study; however since it is a 
constant factor in calculations it would not influence relative differences observed 
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between the two forms of Fe.  Another limitation in the study design was associated 
with our ability to assess tracer enrichment only in the RBC; other non-hemoglobin 
associated neonatal pools are not captured.  Because the majority of neonatal Fe (75-
80%) (26) is found as circulating hemoglobin the impact of this limitation may not be 
substantial. Thus, assumptions in our calculations are unlikely to account for the 
preferential transfer of heme Fe to the neonate during pregnancy.   
To date, cellular mechanisms of heme uptake and export are not well 
characterized. In particular it is not known if all heme is degraded within the cell into 
inorganic Fe and then exits as inorganic Fe, or if some heme may be exported intact 
through known heme export proteins (such as Feline leukemia virus subgroup C 
receptor-related protein, FLVCR and Breast cancer resistance protein, BCRP) in the 
enterocyte (27). Interestingly both FLVCR (28) and BCRP (29) are most highly 
expressed in the placenta compared to all other tissues in the body which may suggest 
that the placenta does utilize heme Fe.   
Placental transport of orally administered Fe is impacted by factors that affect 
cellular transport in both the enterocyte and the placenta. It is interesting to note that 
while we observed correlations between neonatal heme Fe enrichment and maternal 
serum hepcidin, we found no significant association between maternal serum hepcidin 
and maternal utilization of dietary heme Fe (Chapter 3). Previous research has also 
found that mechanisms of hepcidin regulation may be cell type dependent (30), and 
detailed mechanistic studies are needed in the placenta to understand the role of 
hepcidin in regulating heme and non-heme Fe transport across the placenta.  
To our knowledge this is the first study to examine relationships between 
maternal and neonatal serum hepcidin and placental Fe transfer during pregnancy. 
Serum hepcidin in these pregnant women (9.3 μg/L) was significantly lower than that 
observed in their neonates at birth (61.7 μg/L). Hepcidin concentrations in our 
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population are similar but slightly lower than recent maternal (12.4 ng/mL, n = 116 ) 
and neonatal (78.4 ng/mL, n = 137) values published by Ervasti et al., in a group of 
non-anemic women (31). Lower serum hepcidin values may be expected in our 
pregnant subjects because of the high rates of Fe depletion. In our study population 
pregnant subjects with non-detectable serum hepcidin (< 5 μg/L) transferred 
significantly more heme and non-heme Fe to the neonate compared to subjects with 
detectable serum hepcidin. Similar but non-significant trends were evident between 
neonatal serum hepcidin and net Fe transfer. Our data support current findings 
reported in transgenic mice over expressing hepcidin. These mice die shortly after 
birth due to severe Fe deficiency presumably due to insufficient Fe endowment of 
birth caused by a deficit in placental Fe flux to the developing fetus (13).  
In summary, intrinsically labeled heme may be preferentially transported to the 
fetus during the third trimester of pregnancy. Maternal hepcidin is significantly 
associated with placental heme and non-heme Fe transfer. Iron status in the maternal-
neonatal dyad significantly impacts transport of both heme and non-heme Fe to the 
neonate, but a greater percent of the variability of placental heme Fe transfer remains 
to be fully characterized. Further research on the mechanisms of heme Fe metabolism 
and mechanisms of placental Fe transfer are warranted. 
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Abstract 
Objective: To elucidate the role of maternal and neonatal iron status on placental 
transferrin receptor (TfR) expression.  
Methods: Ninety-two healthy pregnant adolescents (ages 14-18 years) were followed 
across pregnancy. Maternal iron status (hemoglobin, hematocrit, serum ferritin, TfR, 
and total body iron) was assessed in mid-gestation (21-25 wks) and at delivery in the 
maternal-neonatal dyad. Placental TfR protein expression was assessed via western 
blot in placental tissue collected at delivery.  
Results: Placental TfR expression was inversely associated with maternal iron status 
at mid-gestation (hemoglobin p = 0.046, r
2
 = 0.1 and hematocrit p = 0.005, r
2
 = 0.24) 
and at delivery (serum ferritin p = 0.02, r
2
 = 0.08 and total body iron p = 0.02, r
2
 = 
0.07). Mothers with depleted body iron stores had significantly greater placental 
expression of TfR than mothers with body iron stores greater than zero (p = 0.003). 
Neonatal iron status (assessed by serum ferritin in cord blood) was also inversely 
associated with the expression of placental TfR (p = 0.04, r
2
 = 0.06). Neonates with 
cord serum ferritin values  ≤ 34 μg/L had significantly greater protein expression of 
placental TfR compared to neonates with cord serum ferritin values > 34 μg/L (p = 
0.01). 
Conclusions: Expression of placental TfR is responsive to both maternal and neonatal 
iron demands. Increased expression of placental TfR may be an important 
compensatory mechanism in response to iron deficiency in otherwise healthy pregnant 
women.  
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Introduction 
Iron deficiency is the most common nutrient deficiency in the world, globally 
impacting 1.62 billion people with highest rates in pregnant women and children (1). 
Reduced neonatal iron status at birth has been associated with impaired mental and 
psychomotor function, altered temperament, impaired neonatal auditory recognition 
memory and impaired auditory brainstem response (2-5). Therefore, understanding 
mechanisms of placental iron transport during the third trimester of pregnancy is 
important to facilitating adequate iron endowment at birth.   
The placenta is a key regulatory organ that is essential for fetal nutrient 
transport. Humans have a hemochorial placenta; maternal blood is in direct contact 
with the fetal chorionic villi.  In the mature hemochorial placenta there are only two 
layers separating maternal and fetal blood, the syncytiotrophoblast (STB), and fetal 
endothelial cells (6). The STB is able to selectively regulate transport of oxygen and 
essential nutrients to the fetus while also allowing for the excretion of fetal waste 
products (ex. carbon dioxide) to be picked up and cleared by maternal circulation. The 
majority of fetal iron stores (75 mg Fe/ kg body weight) are acquired during the third 
trimester of pregnancy  (7). Iron must be actively transported across the STB against a 
concentration gradient in order to meet the fetus’s large iron demands. Thus the 
efficiency of placental iron transfer may set the stage for postnatal iron status and the 
subsequent risk of developing iron deficiency in infancy.  At delivery the neonate 
typically has accrued a large amount of storage iron with normative serum ferritin 
concentrations averaging 134 ug/L at a time when most pregnant women have 
exhausted their ferritin reserves (8). 
Previous research from our lab has indicated potential compensatory 
mechanisms such as increased maternal iron absorption and increased placental iron 
transport may act to mitigate the risk of iron deficiency in the fetus (9;10, Chapters 3 
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and 4). The mechanisms and regulatory signals for increased placental iron transport 
remain unclear. Regulation of key placental iron transporters may allow for greater 
iron uptake and transfer to the fetus. Some researchers have suggested that this 
regulation occurs primarily at uptake rather than efflux stages of placental iron 
transport (11). Transferrin receptor (TfR) is expressed primarily on the apical side of 
the STB membrane where it is responsible for binding maternal diferric transferrin 
(12).  Previous animal and cell culture studies have demonstrated that maternal iron 
deficiency leads to increased transferrin receptor mRNA and protein expression (13). 
Similar upregulation of placental TfR expression has been shown in pregnancies 
complicated with diabetes (12). However, the role of maternal and neonatal iron status 
on regulating placental TfR expression is inconclusive in normal healthy populations 
(14-16). The objective of this research was to assess the determinants of placental TfR 
expression in response to iron status in a population of healthy pregnant adolescents. 
Iron demands during pregnancy may be further elevated in this population due to the 
concurrent iron requirements for growth and development in the adolescent as well as 
requirements for normal pregnancy and fetal growth. This study provides novel data 
on placental TfR expression in a vulnerable population at risk for developing iron 
deficiency.  
 
Subjects and Methods 
Subjects 
Ninety-two pregnant adolescents (14-18 years) were recruited from the 
Rochester Adolescent Maternity Program (RAMP) in Rochester New York. 
Adolescents were eligible to participate if they were otherwise healthy with a 
singleton pregnancy and planning to deliver at Highland Hospital in Rochester. 
Adolescents were excluded if they had a diagnosis of HIV infection, diabetes, 
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preeclampsia, eating disorders, malabsorption diseases, or self-reported drug use. Over 
91% of the adolescents reported not smoking during the pregnancy. All adolescents 
were enrolled in a larger study of maternal and fetal bone health and iron status. 
Informed written consent was obtained from each subject. The study was approved by 
the Institutional Review Boards of Cornell University and the University of Rochester 
and registered with clinicaltrials.gov as NCT01019902 (http://www.clinicaltrials.gov).  
A maternal blood sample was obtained between weeks 21-25 of pregnancy 
(mid-gestation) to examine iron status during pregnancy. Adolescents were followed 
throughout their pregnancy and at delivery maternal and cord blood samples were 
obtained to examine iron status in both the mother and neonate. The placenta was 
collected and processed immediately after delivery. Placental weight (including 
membranes and cord) and dimensions (length, width, thickness, and volume) were 
recorded. Representative placental samples were collected, the maternal and fetal 
membranes removed and sections mixed to provide a representative sampling of 
placental tissue. The mixed sample was aliquoted, frozen on dry ice and sent to 
Cornell for subsequent protein extraction.  The remaining placenta was then placed in 
a placental buffer solution (containing DMEM, HEPES, NaHCO3 and 100X 
Pen/Strep/Neo) and shipped to Cornell for further processing. Representative placental 
samples were also taken with both the maternal and fetal membranes intact for total 
iron quantification of whole placenta tissue. Total placental Fe content was analyzed 
by atomic absorption spectrophotometry (AAS) (PerkinElmer Analyst 800; 
PerkinElmer Inc, Norwalk, CT). All placental samples were stored at -80°C.  
 
Western Blot Analysis 
For protein extraction, placental tissue was kept at 4°C at all times, rinsed in 
0.9% saline and homogenized in lysis buffer (containing 1.5 M Tris, 1.0 M CaCl2, 
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Triton X-100, and protease inhibitor) at ~5000 RPM. Samples were centrifuged for 25 
minutes at 14,000g at 4°C and the supernatant was assayed for total protein 
concentration using the BioRad protein assay method (BioRad, Richmond CA).  
Supernatants were stored at -80°C until use. Lysates diluted in 6X SDS sample buffer 
were stored at -20°C prior to Western blot analysis. Protein lysates were run on 10% 
SDS-PAGE gel and transferred to a polyvinylidene difluoride fluorescence (PVDF-
FL) membranes. Protein expression of TfR was analyzed by Western blot analysis 
using a commercially available antibody (Zymed Laboratores, San Francisco CA). 
Actin was used as a loading control (Abcam, Cambridge MA). Secondary antibodies 
(800-goat anti-mouse and 680-goat anti-rabbit) were purchased from Li-Cor 
Biosciences. Membranes were scanned and analyzed with Odyssey Infrared Imaging 
System (Li-Cor Biosciences, Lincoln, NE).  A placenta control sample was loaded on 
all of the gels and used to correct for intra-gel variability.  
 
Laboratory Analysis  
 Hemoglobin (Hb) and hematocrit were analyzed by the Strong Memorial 
Hospital’s clinical laboratory using the Cell Dyn 4000 system. Serum was stored at     
-80°C prior to analysis. Serum ferritin was measured by an enzyme immunoassay 
procedure (Ramco Laboratories, Inc Stafford Texas). Serum soluble transferrin 
receptor was measured with an enzyme linked immunosorbent assay (Ramco 
Laboratories, Inc Stafford Texas). Total body iron (TBI) was calculated based the 
formula provided by Cook et al., (total body iron (mg/kg) = -[log (serum transferrin 
receptor/serum ferritin) – 2.8229]/0.1207) (17).   
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Data analysis 
All statistical analyses were completed using the JMP 8.0 (SAS Institute INC, 
Cary, NC). Normally distributed data are presented as the mean ± standard deviation 
and non-normally distributed data are presented as the median ± standard deviation. 
Variables that were not normally distributed were transformed using the natural log 
prior to statistical testing.  Paired t-tests were used to detect differences within subject 
groups. Differences between subject groups were compared using a t-test or the 
Wilcoxon rank sum test for nonparametric data.  Linear regression analyses were used 
to examine the relationships between iron status indicators and placental expression of 
TfR. Differences were considered significant if p < 0.05.  
 
Results 
Subject characteristics are described in Table 5.1. The majority of the 
adolescent population was African American (64%) and non-Hispanic (71%). For 
87% percent of the adolescents this was their first child. Of the pregnant adolescents 
enrolled in the study only 56% entered pregnancy with a normal BMI (18.5-24.9 
kg/m
2
); 7% were underweight (18.5 kg/m
2
) and 37% entered pregnancy either 
overweight (> 25 kg/m
2
) or obese (> 30 kg/m
2
). The majority of adolescents (98%) 
had term deliveries (≥ 37 weeks gestation) and two adolescents delivered preterm 
(36.6 and 36.9 wks).  One of the preterm infants was also born low birth weight (< 
2500 grams) as were two additional term infants. Iron status indicators for the 
adolescents and neonates are described in Table 5.2. Sample sizes varied for each of 
the biomarkers as limited serum precluded analysis of all indicators in all samples. 
Furthermore, hemoglobin and hematocrit values were pulled from medical charts 
retrospectively and were not available for all subjects enrolled in the study.  
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1
Mean ± SD is given for normally distributed values (range in parentheses) 
2
Non normally distributed values are given as median ± SD 
Table 5.1  
General characteristics of the  92 participants
1
 
Variable   
Age at enrollment (y)
2
 17.0  1.1 (13.6 – 18.7) 
Gestational Age at Delivery (wks)
 2
 
 
 40.0   1.2 (36.6 – 41.7) 
Pre-pregnancy BMI (kg/m
2
)
 2
 23.2  5.3 (15.2 – 38.7) 
Maternal Weight Gain (lbs)
 1
 36.4  13.4 (8 – 80) 
Infant Weight (g)
 1
 3241  499 (2150 – 4705) 
Placenta weight (g)
 1
 605.3  126.4 (271 – 862) 
Race  
      African American 64% 
      Caucasian 35% 
      Other  1% 
Ethnicity  
      Hispanic 29% 
      Non-Hispanic  71% 
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    Table 5.2 
Iron status indicators for pregnant adolescents and neonates
1,2 
Variable 
 
Maternal 
Mid-gestation 
Maternal  
Delivery 
Neonate 
Delivery 
Hemoglobin (g/L) 
    ( % Anemic) 
11.3  1.0 1,a 
19% 
n = 48 
11.7  1.5 1,a 
29% 
n = 62 
14.7  1.7 1,b 
 
n = 32 
    
Serum ferritin (μg/L) 
    < 12 μg/L  
    < 20 μg/L  
 
16.5  16.5 2,a 
35% 
65% 
n = 81 
17.6  13.0 2,a 
31% 
57% 
n = 88 
114.1  81.0 2,b 
 
 
n = 82 
    
Serum TfR (mg/L) 
    > 8.5 mg/L  
 
4.6  2.0 2,a 
5% 
n = 81 
4.6  3.4 2,b 
13% 
n = 88 
8.0  2.4 2,c 
 
n = 83 
    
Total Body Iron (mg/kg) 
    < 0 mg/kg  
 
3.3  3.7 2,a 
22% 
n = 81 
2.8  3.8 1,a 
20% 
n = 87 
8.7  2.8 2,b 
 
n = 82 
1
Mean ± SD is given for normally distributed values, variables that are 
significantly different among groups are denoted with a different letter (p <0.05) 
2
 Non normally distributed values are presented as median ± SD  
 
Iron deficiency was prevalent. In the second trimester of pregnancy 19% of the 
girls were anemic (Hb < 10.5 g/L) and 29% were anemic at delivery (Hb < 11 g/L). In 
the second trimester of pregnancy 35% were iron deficient (serum ferritin < 12 μg/L) 
and 65% had depleted iron stores (serum ferritin < 20 μg/L) with similar levels at 
delivery (31% and 57% respectively). Approximately 20% of the pregnant adolescents 
had depleted total body iron stores (TBI < 0) during pregnancy and at delivery.  
Of the ninety-two adolescents enrolled in the study, eighty placentas (87%) 
were available for protein analysis. Placentas that were not available were either sent 
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directly to the pathology department for clinical indications or were not obtained due 
to difficulties in the logistics of processing shortly after delivery. Figure 5.1 outlines a 
flow chart of the enrolled subjects and presents the sample sizes obtained for each of 
the iron biomarkers in the adolescent and the neonate. Placental TfR protein 
expression was evident in all placental tissue screened but the expression of the 
protein was highly variable with a 5-fold difference observed among this cohort. 
Placental expression of TfR was significantly associated with indicators of maternal 
and neonatal iron status during pregnancy. Placental TfR expression at delivery was 
inversely associated with maternal hemoglobin (p = 0.046, r
2
 = 0.10) and hematocrit at 
mid-gestation (p = 0.005, r
2
 = 0.24). Placental TfR protein expression was also 
inversely associated with maternal serum ferritin (p = 0.02, r
2 
= 0.08 Figure 5.2), and 
maternal total body iron (p = 0.02, r
2
 = 0.07) at delivery.  
Adolescents with iron deficiency at delivery (serum ferritin ≤12 μg/L) had 
significantly greater placental expression of TfR than those with ferritin levels > 12 
μg/L (p = 0.04).  Likewise teens with depleted total body iron stores (TBI < 0) had 
significantly greater placental expression of TfR than those with total body iron stores 
greater than zero (p = 0.003, Figure 5.3).  
At delivery placental TfR expression was also inversely associated with 
neonatal serum ferritin (p = 0.04, r
2
 = 0.06). Infants with cord serum ferritin 
concentrations ≤ 34 μg/L (n = 9) had significantly greater expression of placental TfR 
compared to neonates with cord serum ferritin values > 34 μg/L (n = 75, p = 0.01), 
Figure 5.4. Neonatal serum ferritin was also directly associated with maternal iron 
serum ferritin at mid gestation (p = 0.0006, r
2 
= 0.16) and at delivery (p = 0.04, r
2 
= 
0.05). A model that included both maternal and neonatal serum ferritin at delivery 
explained 12% of the variability in protein expression (p = 0.01, r
2
 = 0.12).
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Figure 5.1 Flow Chart of Available Samples. 
 Iron status indicators were assessed in a cohort of ninety-two pregnant adolescents. 
Of these 92 adolescents, 80/92 (87%) had placental tissue collected at delivery. The 
corresponding charts illustrate the iron status biomarkers available for data analysis.  
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Figure 5.2 Placental TfR Expression and Maternal Serum Ferritin. 
 Placental expression of transferrin receptor (TfR) was examined in relation to 
maternal serum ferritin concentrations at delivery in a group of 76 pregnant 
adolescents (ages 14-18 years). Placental TfR expression at delivery was inversely 
associated with maternal serum ferritin concentrations (p = 0.02, r
2
 = 0.08).     
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Figure 5.3 Placental TfR Expression and Maternal Total Body Iron. 
Placental expression of transferrin receptor (TfR) was examined in relation to maternal 
total body iron at delivery in a group of 75 pregnant adolescents (ages 14-18 years). 
Adolescents with depleted total body iron stores at delivery (n = 14) had significantly 
greater placental expression of TfR when compared to adolescents with total body iron 
stores greater than zero (n = 61, p = 0.003). 
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Figure 5.4 Placental TfR Expression and Neonatal Serum Ferritin. 
 Placental expression of transferrin receptor (TfR) was examined in relation to 
neonatal serum ferritin concentrations at delivery (n = 71). Infants with cord serum 
ferritin concentrations ≤ 34 μg/L (n = 6) had significantly greater protein expression of 
placental TfR (n = 65, p = 0.01). 
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Interestingly, the expression of placental TfR was also inversely associated 
with placental volume (p = 0.003, r
2
 = 0.22) and placental thickness (p = 0.02, r
2
 = 
0.14) but was not significantly associated with placental weight or placental iron 
concentration. Placental TfR was not significantly different in adolescents that self-
reported smoking during pregnancy. The average use of cigarettes among those that 
reported smoking during pregnancy was approximately 8.6 cigarettes per day (ranging 
from 1 – 20 cigarettes per day). Neonatal hemoglobin was slightly but significantly 
elevated in neonates whose mothers smoked during pregnancy (14.5 ± 1.7 vs. 15.9 ± 
0.8, p =0.03). However, maternal iron status, infant weight, placental weight, 
gestational age and other markers of iron status in the neonate were not significantly 
impacted by maternal smoking status.  
 
Discussion  
Placental TfR protein expression was responsive to both maternal and neonatal 
iron demands. Our research confirms data in animal and cell culture models as well as 
that reported from complicated pregnancies in which neonatal iron status was known 
to be adversely impacted (12;13). Our data are unique in that they confirm these 
relationships among a relatively healthy population of adolescents with uncomplicated 
pregnancies.  Previous data obtained in healthy adult populations have been 
inconclusive and were primarily undertaken among much smaller study cohorts (14-
16). Research by Bradley et al., in twenty-one healthy non-anemic women found 
placental TfR expression to be unrelated to neonatal or placental iron status (as 
measured with cord serum ferritin and placental ferritin) (14). Likewise, in a group of 
thirty-eight healthy women that included both iron replete and iron deficient (~20%)  
pregnant women, placental TfR expression was unrelated to maternal iron status 
(hemoglobin, TfR, and serum ferritin); in that study neonatal iron status was not 
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reported (15). In a group of forty healthy pregnant women, relationships between 
protein expression of TfR and maternal iron status approached significance, but a 
significant increase in placental TfR mRNA was evident in subjects with mild anemia 
(90 g/L ≤ Hb < 110 g/L) and no change in those with moderate anemia (Hb < 90 g/L) 
compared to non-anemic women (16). Our study population was a large cohort of 
pregnant adolescents. The racial composition of this group is reflective of the 
increased risk of early childbearing found among US minority populations. In total 
65% of the group was African American and 29% was Hispanic. Adolescents are at 
increased risk of anemia because of the additional demands of maternal growth 
superimposed on those required for the developing fetus.  These differences in study 
design and iron status of our population may have allowed us to detect significant 
differences in placental TfR expression.  
Maternal and neonatal iron stores were significantly associated with placental 
TfR and explained approximately 8% and 6% of the variability in protein expression 
of placental TfR, respectively. A unique aspect of this study is that iron status was 
assessed in the maternal-neonatal dyad whereas many previous studies focused only 
on the neonate or the mother. While it is difficult to tease apart the independent role of 
maternal versus neonatal iron status, when both maternal and neonatal iron status are 
included in a model, substantially more of the variability in protein expression (12%) 
was explained compared to use of either maternal or neonatal status alone. In women 
with depleted total body iron at delivery (TBI < 0) a 29% increase in placental 
expression of TfR was noted compared to mothers with total body iron stores greater 
than zero. Likewise, there was a 26% increase in the expression of placental TfR in the 
placentas of neonates born with cord serum ferritin values ≤ 34 μg/L. In spite of these 
significant associations, the measures of iron status we utilized only explained a 
relatively small fraction of the almost five-fold difference noted in relative protein 
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expression. In research by Li et al., there was an approximate three-fold increase in 
placental TfR mRNA in subjects with mild anemia compared to non-anemic pregnant 
women but only a ~20% non significant increase in placental TfR protein expression 
(16). Because the majority of variability in placental TfR was not explained by iron 
status, other factors that have been linked to placental TfR expression such as IRP-1 
(18) and hepcidin (19) warrant further investigation.  
Despite evidence of upregulation of placental TfR in response to reduced iron 
stores, this compensatory mechanism may not be sufficient to achieve optimal iron 
stores in the neonate at birth.  Although no clear cut offs exist to define suboptimal 
neonatal iron stores, our cord serum ferritin values can be compared to values that 
have been associated with impaired functional outcomes in other populations.  
Approximately 9% of the neonates in this study were born with cord serum ferritin 
values  ≤ 34 μg/L, a level reported to be suspected of brain iron deficiency (2). 
Siddappa et al., reported that infants born to diabetic mothers with cord serum ferritin 
≤ 34 μg/L had impaired infant auditory recognition memory as well as lower 
psychomotor development scores after one year compared to infants born to diabetic 
mothers with cord serum ferritin > 34 μg/L (2).  This is in accordance with previous 
research in infants of mothers with diabetes who were born with reduced liver, heart 
and brain iron (12;20) despite increased placental TfR expression (12). Thus the 
placenta’s ability to upregulate placental iron transport to compensate for limited iron 
availability may not be sufficient to endow the neonate with optimal iron stores in the 
face of suboptimal maternal iron status.  
In summary, in an otherwise healthy group in whom nutrient needs are likely 
challenged by increased maternal needs coupled with pregnancy demands we found 
placental TfR protein expression to be responsive to both maternal and neonatal iron 
status. Regulation of placental TfR expression may be an important compensatory 
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mechanism to increase iron flux to the developing fetus. More research is needed to 
understand the role and regulation of other placental iron transporters in response to 
maternal and neonatal iron status.  
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CHAPTER 6 
 
 SUMMARY AND CONCLUSIONS
140 
Summary 
 The research presented provides novel insight into some of the key 
determinants of heme and non-heme iron absorption and placental iron transfer in a 
group at high risk for iron deficiency. There were four key specific aims of this 
research that were described in Chapters 2-5, respectively. Below is a brief summary 
of the specific aims, outcomes and implications of the findings generated. 
 For many years the systemic hormone responsible for whole body iron 
homeostasis had not been identified. This changed in 2000 when the small peptide 
hepcidin was identified (1). Because this was only a 25 amino acid peptide, the small 
size made it difficult for assays to accurately measure this hormone. For these 
technical reasons, many researchers measured prohepcidin, a 60-AA precursor of 
hepcidin, as marker for hepcidin expression. My first specific aim was to assess 
relationships between serum hepcidin and serum prohepcidin with non-heme iron 
absorption from an iron supplement and an orange flesh sweet potato source in a 
group of healthy non-pregnant women.  Using stable iron isotopes and a newly 
developed assay for hepcidin we published the first data demonstrating a significant 
inverse relationship between hepcidin and non-heme iron absorption (2). Of interest, 
only ~25% of the variability in non-heme iron absorption was explained by this 
hormone, a similar amount of variability can be explained simply with the use of iron 
stores (serum ferritin).  This finding was published in the American Journal of 
Clinical Nutrition along with an editorial highlighting its significance (3), and was 
subsequently replicated by other research groups (4;5). Serum prohepcidin, on the 
other hand, was not significantly related to measures of iron absorption or serum 
hepcidin and may not serve as a useful substitute for serum hepcidin.   
My second specific aim was to build on the results of the first study and 
examine the impact of iron status and serum hepcidin on both heme and non-heme 
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iron absorption in non-pregnant and pregnant women. Stable isotopes were again 
utilized to assess iron absorption from heme and non-heme iron sources (
58
Fe-
intrinsically labeled heme and 
57
Fe as ferrous sulfate). This was the first human study 
to my knowledge to assess heme iron metabolism during pregnancy and little is known 
about the role of serum hepcidin in regulating heme iron absorption. Pregnant and 
non-pregnant women absorbed significantly more iron from the heme-based iron meal 
compared to absorption from the non-heme source. Serum hepcidin was inversely 
associated with non-heme iron absorption but was unrelated to absorption of heme 
iron. Absorption from the non-heme iron source was also more sensitive to iron stores 
than heme iron. Heme iron from animal based foods provided a highly bioavailable 
source of dietary iron during pregnancy. The lack of association of iron stores and 
serum hepcidin with heme iron absorption, yet strong correlations with non-heme iron 
absorption, highlights the differential mechanisms of transport of heme versus non-
heme iron across the enterocyte.   
My third specific aim was to elucidate determinants of heme and non-heme 
placental iron transfer to the fetus over the last trimester of pregnancy. Pregnant 
women that had received the iron isotopes during the third trimester of pregnancy 
were followed to delivery. At parturition, data on iron status and serum hepcidin in the 
maternal-neonatal dyad were examined in relation to isotopic enrichment in the cord 
blood.  Significantly more heme iron was transferred to the neonate than non-heme 
iron, even after accounting for the amount of iron absorbed by the mother. Net 
neonatal non-heme and heme iron transfer (mg) were significantly related to iron 
status in the maternal-neonatal dyad and inversely associated with maternal serum 
hepcidin.  This study provides novel findings that there may be preferential fetal 
utilization of maternally ingested heme iron compared to non-heme iron during 
pregnancy. This implies differential pathways of heme versus non-heme iron entry 
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into the placenta. For this to occur it suggests that at least some dietary heme iron not 
only enters but also exits the enterocyte intact through separate mechanism as 
proposed in Figure 1.1.b in Chapter 1. This may also explain why a significant 
relationship was observed between serum hepcidin and absorption of non-heme iron 
but not heme iron. Hepcidin’s primary mechanism of impacting iron absorption is 
binding to ferroportin (the sole indentified non-heme iron exporter in the enterocyte) 
leading to its internalization and degradation. If some of the heme iron were to exit the 
enterocyte intact through the heme exporters that are known to be present in the 
enterocyte it may explain the lack of association with serum hepcidin and the 
preferential transfer of heme iron to the neonate. However it is possible that there is a 
combination of Figures 1.1.a and 1.1.b and further research is needed on the cell type 
specific mechanisms of hepcidin in the enterocyte and the placenta.  
My final specific aim was to assess determinants of placental TfR protein 
expression in the placenta. Limited data previously existed on the placenta’s ability to 
upregulate iron transporter expression in response to iron status in a healthy 
population. In a large group of ninety-two healthy pregnant adolescents, expression of 
placental TfR was inversely associated with iron status in the maternal-neonatal dyad. 
Increased expression of placental TfR may be an important compensatory mechanism 
in response to iron deficiency during pregnancy. 
Based on the combined results of Chapters 2-5, conceptual frameworks 
(Figure 6.1.a and Figure 6.1.b) for non-heme iron and heme iron metabolism during 
pregnancy have been developed to summarize results.  
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Figure 6.1.a Non-heme Iron Metabolism Conceptual Framework 
Solid black lines represent significant relationships that have been presented in 
previous chapters. Gray dashed lines with red slashes represent non-significant 
relationships that have been presented in previous chapters. The red dotted lines 
represent presumed or hypothesized relationships that were not directly tested with 
this research. 
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Figure 6.1.b Heme Iron Metabolism Conceptual Framework  
Solid black lines represent significant relationships that have been presented in 
previous chapters. Gray dashed lines with red dashes represent non-significant 
relationships that have been presented in previous chapters. The red dotted lines 
represent presumed or hypothesized relationships that were not directly tested with 
this research. 
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In brief, from Figure 6.1.a non-heme iron absorption was dependent on the 
bioavailability of the meal (greater iron absorption from the liquid iron supplement 
compared to the orange flesh sweet potato meal). Non-heme iron absorption was 
inversely associated with maternal iron status and serum hepcidin, which are in turn 
were correlated, but iron status appeared to be the major factor influencing non-heme 
iron absorption. It is hypothesized that the diet in turn will directly impact the iron 
status of the individual. Non-heme iron transfer was also inversely correlated with 
both maternal iron status and serum hepcidin. Again maternal iron status was the 
primary determinant of non-heme iron transfer, explaining the majority of the 
variability. Non-heme iron transfer was also associated with neonatal iron status which 
was in turn correlated with the mothers iron status. Although neonatal iron status was 
highly correlated with neonatal serum hepcidin, neonatal serum hepcidin was not 
significantly correlated with iron transfer or maternal serum hepcidin. Altered iron 
stores in both the mother and neonate were able to increase the expression of placental 
TfR. Although, not directly tested, it is hypothesized that the increased expression of 
key placental iron transport proteins in turn acts to increase net flux to the fetus. 
Likewise we see a similar picture for heme iron metabolism (Figure 6.1.b) with two 
key exceptions. Heme iron absorption was not significantly associated with maternal 
iron status or serum hepcidin although these factors do appear to directly impact 
placental heme iron transport. The expression of heme iron transporters in the placenta 
were not assessed, however a similar trend is hypothesized. Although Figures 6.1.a 
and 6.1.b are simplified and other factors including age, CRP and EPO have been 
shown be correlated with some of the variables, the diagrams still give a good basic 
outline of the primary relationships driving iron metabolism examined in this research. 
This data provides novel information on heme iron metabolism, serum hepcidin and 
mechanisms of upregulating iron transfer during pregnancy.  
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Future Directions 
 Based on the results of this study further research is warranted to investigate 
molecular mechanisms of heme iron absorption and placental iron transport in order to 
elucidate the pathways of preferential absorption and transfer of heme iron. Only one 
iron transport protein in the placenta was examined in this research and future studies 
should examine the role of other non-heme and heme iron transporters (ferroportin, 
DMT1, FLVCR, hemopexin receptor, etc) not only with respect to protein expression 
but also RNA expression. Furthermore, molecular studies on how hepcidin regulates 
iron metabolism during pregnancy are also needed. 
 Despite increased iron absorption, placental expression of iron transport 
proteins and iron transfer to the neonate, many mothers and infants still had 
suboptimal iron status at birth. Over 50% of the mothers had depleted iron stores at 
delivery and in the large cohort of pregnant adolescents (Chapter 5) almost 10% of the 
neonates were born with cord serum ferritin values ≤ 34 µg/L. Further research is 
needed to design interventions to prevent the onset of iron deficiency during 
pregnancy in order to optimize iron stores at birth. Compliance with prenatal iron 
supplementation is often a problem in this teen population. Qualitative studies on the 
barriers for adherence would provide valuable insight in how to improve consumption 
of supplements during pregnancy. The addition of heme iron sources to the diet may 
provide a highly bioavailable iron source, but studies on availability, access and 
acceptance are required. Furthermore, research on the functional consequences of iron 
deficiency during pregnancy on both the mother and neonate is necessary; as pregnant 
teens may be at elevated risk due to the high iron demands of pregnancy concurrent 
with the iron demands of the growing adolescent.  
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